| Year |
Citation |
Score |
| 2024 |
Li Z, Ma R, Tang H, Guo J, Shah Z, Zhang J, Liu N, Cao S, Marcucci G, Artis D, Caligiuri MA, Yu J. Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death. Cell. PMID 38211590 DOI: 10.1016/j.cell.2023.12.015 |
0.347 |
|
| 2023 |
Mansour AG, Teng KY, Li Z, Zhu Z, Chen H, Tian L, Ali A, Zhang J, Lu T, Ma S, Lin CM, Caligiuri MA, Yu J. Off-the-Shelf CAR-Engineered Natural Killer Cells Targeting FLT3 Enhance Killing of Acute Myeloid Leukemia. Blood Advances. PMID 37379267 DOI: 10.1182/bloodadvances.2022007405 |
0.422 |
|
| 2023 |
Kumar A, Taghi Khani A, Duault C, Aramburo S, Sanchez Ortiz A, Lee SJ, Chan A, McDonald T, Huang M, Lacayo NJ, Sakamoto KM, Yu J, Hurtz C, Carroll M, Tasian SK, ... ... Caligiuri MA, et al. Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia. Journal For Immunotherapy of Cancer. 11. PMID 37217248 DOI: 10.1136/jitc-2022-006649 |
0.34 |
|
| 2023 |
Yu J, Caligiuri MA. Viral- and tumor-reactive natural killer cells. Seminars in Immunology. 67: 101749. PMID 36965383 DOI: 10.1016/j.smim.2023.101749 |
0.356 |
|
| 2023 |
Ma S, Han J, Li Z, Xiao S, Zhang J, Yan J, Tang T, Barr T, Kraft AS, Caligiuri MA, Yu J. An XBP1s-PIM-2 positive feedback loop controls IL-15-mediated survival of natural killer cells. Science Immunology. 8: eabn7993. PMID 36897958 DOI: 10.1126/sciimmunol.abn7993 |
0.405 |
|
| 2023 |
Hong B, Sahu U, Mullarkey MP, Hong E, Pei G, Yan Y, Otani Y, Banasavadi-Siddegowda Y, Fan H, Zhao Z, Yu J, Caligiuri MA, Kaur B. PKR induces TGF-β and limits oncolytic immune therapy. Journal For Immunotherapy of Cancer. 11. PMID 36796878 DOI: 10.1136/jitc-2022-006164 |
0.453 |
|
| 2023 |
Caligiuri M, Li Z, Ma R, Tang H, Zhang J, Marcucci G, Yu J. Human ILC1s target leukemia stem cells and control development of AML. Research Square. PMID 36711868 DOI: 10.21203/rs.3.rs-2319959/v1 |
0.327 |
|
| 2022 |
Tian L, Xu B, Chen Y, Li Z, Wang J, Zhang J, Ma R, Cao S, Hu W, Chiocca EA, Kaur B, Caligiuri MA, Yu J. Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity. Nature Cancer. PMID 36357700 DOI: 10.1038/s43018-022-00448-0 |
0.5 |
|
| 2022 |
Ma S, Caligiuri MA, Yu J. Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy. Trends in Immunology. PMID 36058806 DOI: 10.1016/j.it.2022.08.004 |
0.363 |
|
| 2022 |
Lu T, Ma R, Dong W, Teng KY, Kollath DS, Li Z, Yi J, Bustillos C, Ma S, Tian L, Mansour AG, Li Z, Settles EW, Zhang J, Keim PS, ... ... Caligiuri MA, et al. Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19. Nature Communications. 13: 2576. PMID 35546150 DOI: 10.1038/s41467-022-30216-8 |
0.393 |
|
| 2022 |
Li Z, Ma R, Ma S, Tian L, Lu T, Zhang J, Mundy-Bosse BL, Zhang B, Marcucci G, Caligiuri MA, Yu J. ILC1s control leukemia stem cell fate and limit development of AML. Nature Immunology. PMID 35487987 DOI: 10.1038/s41590-022-01198-y |
0.335 |
|
| 2022 |
Xiao R, Mansour AG, Huang W, Hassan QN, Wilkins RK, Komatineni SV, Bates R, Ali S, Chrislip LA, Queen NJ, Ma S, Yu J, Lordo MR, Mundy-Bosse BL, Caligiuri MA, et al. Adipocyte CD1d Gene Transfer Induces T Cell Expansion and Adipocyte Inflammation in CD1d Knockout Mice. Journal of Immunology (Baltimore, Md. : 1950). PMID 35418470 DOI: 10.4049/jimmunol.2100313 |
0.315 |
|
| 2022 |
Ma S, Caligiuri MA, Yu J. A four-stage model for murine natural killer cell development in vivo. Journal of Hematology & Oncology. 15: 31. PMID 35313938 DOI: 10.1186/s13045-022-01243-1 |
0.367 |
|
| 2022 |
Mundy-Bosse BL, Weigel C, Wu YZ, Abdelbaky S, Youssef Y, Casas SB, Polley N, Ernst G, Young KA, McConnell KK, Nalin AP, Wu KG, Broughton M, Lordo MR, Altynova E, ... ... Caligiuri MA, et al. Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma. Blood Cancer Discovery. 3: 154-169. PMID 35247900 DOI: 10.1158/2643-3230.BCD-21-0098 |
0.829 |
|
| 2022 |
Ma S, Tang T, Wu X, Mansour AG, Lu T, Zhang J, Wang LS, Caligiuri MA, Yu J. PDGF-D-PDGFRβ signaling enhances IL-15-mediated human natural killer cell survival. Proceedings of the National Academy of Sciences of the United States of America. 119. PMID 35027451 DOI: 10.1073/pnas.2114134119 |
0.361 |
|
| 2021 |
Tian L, Xu B, Teng KY, Song M, Zhu Z, Chen Y, Wang J, Zhang J, Feng M, Kaur B, Rodriguez-Rodriguez L, Caligiuri MA, Yu J. Targeting Fc receptor-mediated effects and the "don't eat me" signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34645647 DOI: 10.1158/1078-0432.CCR-21-1248 |
0.509 |
|
| 2021 |
Xu B, Tian L, Chen J, Wang J, Ma R, Dong W, Li A, Zhang J, Antonio Chiocca E, Kaur B, Feng M, Caligiuri MA, Yu J. An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma. Nature Communications. 12: 5908. PMID 34625564 DOI: 10.1038/s41467-021-26003-6 |
0.473 |
|
| 2021 |
Lordo MR, Wu KG, Altynova E, Shilo N, Kronen P, Nalin AP, Weigel C, Zhang X, Yu J, Oakes CC, Caligiuri MA, Freud AG, Mundy-Bosse BL. Acute Myeloid Leukemia Alters Group 1 Innate Lymphoid Cell Differentiation from a Common Precursor. Journal of Immunology (Baltimore, Md. : 1950). PMID 34417259 DOI: 10.4049/jimmunol.2100023 |
0.694 |
|
| 2021 |
Lu T, Ma R, Li Z, Mansour AG, Teng KY, Chen L, Zhang J, Barr T, Caligiuri MA, Yu J. Hijacking TYRO3 from tumor cells via trogocytosis enhances NK-cell effector functions and proliferation. Cancer Immunology Research. PMID 34326137 DOI: 10.1158/2326-6066.CIR-20-1014 |
0.37 |
|
| 2021 |
Ma S, Yan J, Barr T, Zhang J, Chen Z, Wang LS, Sun JC, Chen J, Caligiuri MA, Yu J. The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity. The Journal of Experimental Medicine. 218. PMID 34160549 DOI: 10.1084/jem.20210279 |
0.383 |
|
| 2021 |
Duault C, Kumar A, Taghi Khani A, Lee SJ, Yang L, Huang M, Hurtz C, Manning B, Ghoda LY, McDonald T, Lacayo NJ, Sakamoto KM, Carroll MP, Tasian SK, Marcucci G, ... ... Caligiuri MA, et al. Activated Natural Killer Cells Predict Poor Clinical Prognosis in High-risk B- and T- cell Acute Lymphoblastic Leukemia. Blood. PMID 34077953 DOI: 10.1182/blood.2020009871 |
0.381 |
|
| 2021 |
Ma R, Lu T, Li Z, Teng KY, Mansour AG, Yu M, Tian L, Xu B, Ma S, Zhang J, Barr T, Peng Y, Caligiuri MA, Yu J. An oncolytic virus expressing IL-15/IL-15Rα combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma. Cancer Research. PMID 34006525 DOI: 10.1158/0008-5472.CAN-21-0035 |
0.427 |
|
| 2021 |
Bergin SM, Xiao R, Huang W, Judd CRT, Liu X, Mansour AG, Queen N, Widstrom KJ, Caligiuri MA, Cao L. Environmental activation of a hypothalamic BDNF-adipocyte IL-15 axis regulates adipose- natural killer cells. Brain, Behavior, and Immunity. PMID 33989745 DOI: 10.1016/j.bbi.2021.05.005 |
0.364 |
|
| 2021 |
Bill M, Goda C, Pepe F, Ozer HG, McNeil B, Zhang X, Karunasiri M, Kulkarni R, Kalyan S, Papaioannou D, Ferenchak G, Garzon R, Bradner JE, Marcucci G, Caligiuri MA, et al. Targeting BRD4 in acute myeloid leukemia with partial tandem duplication of the gene. Haematologica. PMID 33979989 DOI: 10.3324/haematol.2020.271627 |
0.622 |
|
| 2021 |
Lordo MR, Scoville SD, Goel A, Yu J, Freud AG, Caligiuri MA, Mundy-Bosse BL. Unraveling the Role of Innate Lymphoid Cells in AcuteMyeloid Leukemia. Cancers. 13. PMID 33477248 DOI: 10.3390/cancers13020320 |
0.67 |
|
| 2021 |
Lewinsky H, Gunes EG, David K, Radomir L, Kramer MP, Pellegrino B, Perpinial M, Chen J, He TF, Mansour A, Teng KY, Bhattacharya S, Caserta E, Troadec E, Lee PP, ... ... Caligiuri MA, et al. CD84 is a regulator of the immunosuppressive microenvironment in Multiple Myeloma. Jci Insight. PMID 33465053 DOI: 10.1172/jci.insight.141683 |
0.336 |
|
| 2021 |
Lu T, Chen L, Mansour AG, Yu MJ, Brooks N, Teng KY, Li Z, Zhang J, Barr T, Yu J, Caligiuri MA. Cbl-b Is Upregulated and Plays a Negative Role in Activated Human NK Cells. Journal of Immunology (Baltimore, Md. : 1950). PMID 33419766 DOI: 10.4049/jimmunol.2000177 |
0.397 |
|
| 2020 |
Yilmaz A, Cui H, Caligiuri MA, Yu J. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. Journal of Hematology & Oncology. 13: 168. PMID 33287875 DOI: 10.1186/s13045-020-00998-9 |
0.343 |
|
| 2020 |
Mansour AG, Xiao R, Bergin SM, Huang W, Chrislip LA, Zhang J, Ali S, Queen NJ, Caligiuri MA, Cao L. Enriched environment enhances NK cell maturation through hypothalamic BDNF in male mice. European Journal of Immunology. PMID 33169371 DOI: 10.1002/eji.201948358 |
0.323 |
|
| 2020 |
Nalin AP, Kowalski JJ, Sprague AC, Schumacher BK, Gerhardt AG, Youssef Y, Vedantam KV, Zhang X, Siebel CW, Mace EM, Caligiuri MA, Mundy-Bosse BL, Freud AG. Notch Regulates Innate Lymphoid Cell Plasticity during Human NK Cell Development. Journal of Immunology (Baltimore, Md. : 1950). PMID 33020148 DOI: 10.4049/jimmunol.2000434 |
0.666 |
|
| 2020 |
Glorioso JC, Cohen JB, Goins WF, Hall B, Jackson JW, Kohanbash G, Amankulor N, Kaur B, Caligiuri MA, Chiocca EA, Holland EC, Quéva C. Oncolytic HSV Vectors and Anti-Tumor Immunity. Current Issues in Molecular Biology. 41: 381-468. PMID 32938804 DOI: 10.21775/Cimb.041.381 |
0.499 |
|
| 2020 |
Vitale M, Caligiuri MA, Sivori S. Editorial: Natural Killer Cells in Tissue Compartments. Frontiers in Immunology. 11: 258. PMID 32153578 DOI: 10.3389/Fimmu.2020.00258 |
0.35 |
|
| 2020 |
Otani Y, Yoo JY, Chao S, Liu J, Jaime-Ramirez AC, Lee TJ, Hurwitz B, Yan Y, Dai H, Glorioso JC, Caligiuri MA, Yu J, Kaur B. Oncolytic HSV infected glioma cells activate NOTCH in adjacent tumor cells sensitizing tumors to gamma secretase inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32139403 DOI: 10.1158/1078-0432.Ccr-19-3420 |
0.52 |
|
| 2020 |
Yu M, Mansour AG, Teng K, Sun G, Shi Y, Caligiuri MA. Abstract 3313: iPSC-derived natural killer cells expressing EGFR-CAR against glioblastoma Immunology. DOI: 10.1158/1538-7445.Am2020-3313 |
0.367 |
|
| 2019 |
Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, Tandler C, Mbarga M, Schaefer T, Falcone M, Nievergall E, Dörfel D, Hanns P, Passweg JR, Lutz C, ... ... Caligiuri MA, et al. Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature. PMID 31367045 DOI: 10.1038/S41586-019-1475-X |
0.306 |
|
| 2019 |
Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, Tandler C, Mbarga M, Schaefer T, Falcone M, Nievergall E, Dörfel D, Hanns P, Passweg JR, Lutz C, ... ... Caligiuri MA, et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature. PMID 31316209 DOI: 10.1038/S41586-019-1410-1 |
0.494 |
|
| 2019 |
McMichael EL, Benner B, Atwal LS, Courtney NB, Mo X, Davis ME, Campbell AR, Duggan MC, Williams K, Martin K, Levine K, Olaverria Salavaggione GN, Noel T, Ganju A, Uppati S, ... ... Caligiuri MA, et al. A phase I/II trial of cetuximab in combination with interleukin-12 administered to patients with unresectable primary or recurrent head and neck squamous cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31142501 DOI: 10.1158/1078-0432.Ccr-18-2108 |
0.433 |
|
| 2019 |
Xiao R, Mansour AG, Huang W, Chrislip LA, Wilkins RK, Queen NJ, Youssef Y, Mao HC, Caligiuri MA, Cao L. Adipocytes: A Novel Target for IL-15/IL-15Rα Cancer Gene Therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 30833178 DOI: 10.1016/J.Ymthe.2019.02.011 |
0.444 |
|
| 2019 |
Xu B, Ma R, Russell L, Yoo JY, Han J, Cui H, Yi P, Zhang J, Nakashima H, Dai H, Chiocca EA, Kaur B, Caligiuri MA, Yu J. Amendments: Publisher Correction: An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. Nature Biotechnology. 37: 102. PMID 30605164 DOI: 10.1038/Nbt0119-102C |
0.498 |
|
| 2019 |
Wang Y, Zhang Y, Yi P, Dong W, Nalin AP, Zhang J, Zhu Z, Chen L, Benson DM, Mundy-Bosse BL, Freud AG, Caligiuri MA, Yu J. The IL-15-AKT-XBP1s signaling pathway contributes to effector functions and survival in human NK cells. Nature Immunology. 20: 10-17. PMID 30538328 DOI: 10.1038/S41590-018-0265-1 |
0.806 |
|
| 2019 |
Weigel C, Mundy-Bosse BL, Wu Y, McConnell K, Mishra A, Caligiuri MA, Baiocchi RA, Natkunam Y, Porcu P, Brammer J, Freud AG, Oakes CC. Abstract LB-102: Extranodal natural killer/T cell lymphoma (ENKTL) exhibits an unprecedented degree of global DNA hypermethylation, providing a potent targeted therapy in vivo Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Lb-102 |
0.645 |
|
| 2019 |
Otani Y, Young Yoo J, Chao S, Liu J, Cristina Jaime-Ramirez A, Jin Lee T, Hurwitz B, Yan Y, Dai H, Glorioso JC, Caligiuri MA, Yu J, Kaur B. CSIG-23. NOTCH ACTIVATION INDUCED BY HSV-1 ENCODED miRNA-H16 SENSITIZES oHSV-TREATED TUMORS TO NOTCH INHIBITOR Neuro-Oncology. 21: vi49-vi49. DOI: 10.1093/Neuonc/Noz175.193 |
0.518 |
|
| 2018 |
Scoville SD, Freud AG, Caligiuri MA. Cellular pathways in the development of human and murine innate lymphoid cells. Current Opinion in Immunology. 56: 100-106. PMID 30579240 DOI: 10.1016/J.Coi.2018.11.003 |
0.68 |
|
| 2018 |
Russell L, Swanner J, Jaime-Ramirez AC, Wang Y, Sprague A, Banasavadi-Siddegowda Y, Yoo JY, Sizemore GM, Kladney R, Zhang J, Lehman NL, Ostrowski MC, Hong B, Caligiuri M, Yu J, et al. PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance. Nature Communications. 9: 5006. PMID 30479334 DOI: 10.1038/S41467-018-07344-1 |
0.556 |
|
| 2018 |
Xu B, Ma R, Russell L, Yoo JY, Han J, Cui H, Yi P, Zhang J, Nakashima H, Dai H, Chiocca EA, Kaur B, Caligiuri MA, Yu J. An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. Nature Biotechnology. PMID 30475349 DOI: 10.1038/Nbt.4302 |
0.58 |
|
| 2018 |
Xiao R, Bergin SM, Huang W, Mansour AG, Liu X, Judd RT, Widstrom KJ, Queen N, Wilkins R, Siu JJ, Ali S, Caligiuri MA, Cao L. Enriched environment regulates thymocyte development and alleviates experimental autoimmune encephalomyelitis in mice. Brain, Behavior, and Immunity. PMID 30287389 DOI: 10.1016/J.Bbi.2018.09.028 |
0.382 |
|
| 2018 |
Chen L, Youssef Y, Robinson C, Ernst GF, Carson MY, Young KA, Scoville SD, Zhang X, Harris R, Sekhri P, Mansour AG, Chan WK, Nalin AP, Mao HC, Hughes T, ... ... Caligiuri MA, et al. CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity. PMID 30193847 DOI: 10.1016/J.Immuni.2018.08.010 |
0.722 |
|
| 2018 |
Wang Y, Chu J, Yi P, Dong W, Saultz JN, Wang Y, Wang H, Scoville SD, Zhang J, Wu LC, Deng Y, He X, Mundy-Bosse BL, Freud AG, Wang LS, ... Caligiuri MA, et al. SMAD4 promotes TGF-β-independent NK cell homeostasis and maturation and antitumor immunity. The Journal of Clinical Investigation. PMID 30183689 DOI: 10.1172/Jci121227 |
0.687 |
|
| 2018 |
Scoville SD, Nalin AP, Chen L, Chen L, Zhang M, McConnell K, Beceiro Casas S, Ernst G, Traboulsi AA, Hashi N, Williams M, Zhang X, Hughes T, Mishra A, Benson DM, ... ... Caligiuri MA, et al. Human AML activates the AHR pathway to impair NK cell development and function. Blood. PMID 30158248 DOI: 10.1182/Blood-2018-03-838474 |
0.716 |
|
| 2018 |
Hayashi Y, Zhang Y, Yokota A, Yan X, Liu J, Choi K, Li B, Sashida G, Peng Y, Xu Z, Huang R, Zhang L, Freudiger GM, Wang J, Dong Y, ... ... Caligiuri MA, et al. Pathobiologic Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes. Cancer Discovery. PMID 30139811 DOI: 10.1158/2159-8290.Cd-17-1203 |
0.323 |
|
| 2018 |
Yi L, Chen L, Guo X, Lu T, Wang H, Ji X, Zhang J, Ren Y, Pan P, Kinghorn AD, Huang X, Wang LS, Fan Z, Caligiuri MA, Yu J. A Synthetic Disaccharide Derivative of Diphyllin, TAARD, Activates Human Natural Killer Cells to Secrete Interferon-Gamma Toll-Like Receptor-Mediated NF-κB and STAT3 Signaling Pathways. Frontiers in Immunology. 9: 1509. PMID 30072983 DOI: 10.3389/Fimmu.2018.01509 |
0.447 |
|
| 2018 |
Mundy-Bosse B, Denlinger N, McLaughlin E, Chakravarti N, Hwang S, Chen L, Mao HC, Kline D, Youssef Y, Kohnken R, Lee DA, Lozanski G, Freud AG, Porcu P, William B, ... Caligiuri MA, et al. Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma. Blood Advances. 2: 1818-1827. PMID 30054309 DOI: 10.1182/Bloodadvances.2018020388 |
0.737 |
|
| 2018 |
Li X, Dong W, Nalin AP, Wang Y, Pan P, Xu B, Zhang Y, Tun S, Zhang J, Wang LS, He X, Caligiuri MA, Yu J. The natural product chitosan enhances the anti-tumor activity of natural killer cells by activating dendritic cells. Oncoimmunology. 7: e1431085. PMID 29872557 DOI: 10.1080/2162402X.2018.1431085 |
0.495 |
|
| 2018 |
Chan WK, Kang S, Youssef Y, Glankler EN, Barrett ER, Carter AM, Ahmed EH, Prasad A, Chen L, Zhang J, Benson DM, Caligiuri MA, Yu J. A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma. Cancer Immunology Research. PMID 29769244 DOI: 10.1158/2326-6066.Cir-17-0649 |
0.423 |
|
| 2018 |
Wang Y, Dong W, Zhang Y, Caligiuri MA, Yu J. Dependence of innate lymphoid cell 1 development on NKp46. Plos Biology. 16: e2004867. PMID 29702643 DOI: 10.1371/Journal.Pbio.2004867 |
0.483 |
|
| 2018 |
Kim Y, Yoo JY, Lee TJ, Liu J, Yu J, Caligiuri MA, Kaur B, Friedman A. Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy. Proceedings of the National Academy of Sciences of the United States of America. PMID 29686060 DOI: 10.1073/Pnas.1715295115 |
0.598 |
|
| 2018 |
Wang Y, Zhang Y, Hughes T, Zhang J, Caligiuri MA, Benson DM, Yu J. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo Expanded Autologous NK Cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29666301 DOI: 10.1158/1078-0432.Ccr-17-3117 |
0.416 |
|
| 2018 |
Mims AS, Mishra A, Orwick S, Blachly J, Klisovic RB, Garzon R, Walker AR, Devine SM, Walsh KJ, Vasu S, Whitman S, Marcucci G, Jones D, Heerema NA, Lozanski G, ... Caligiuri MA, et al. A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. Haematologica. PMID 29567781 DOI: 10.3324/Haematol.2017.186890 |
0.302 |
|
| 2018 |
Dai HS, Caligiuri MA. Molecular Basis for the Recognition of Herpes Simplex Virus Type 1 Infection by Human Natural Killer Cells. Frontiers in Immunology. 9: 183. PMID 29483911 DOI: 10.3389/Fimmu.2018.00183 |
0.406 |
|
| 2018 |
Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, ... ... Caligiuri MA, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nature Medicine. PMID 29431743 DOI: 10.1038/Nm.4484 |
0.514 |
|
| 2018 |
Stiff A, Trikha P, Mundy-Bosse BL, McMichael EL, Mace TA, Benner B, Kendra K, Campbell A, Gautam S, Abood D, Landi I, Hsu V, Duggan MC, Wesolowski R, Old M, ... ... Caligiuri MA, et al. Nitric Oxide Production by Myeloid Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29363526 DOI: 10.1158/1078-0432.Ccr-17-0691 |
0.407 |
|
| 2018 |
Nakashima H, Alayo QA, Penaloza-MacMaster P, Freeman GJ, Kuchroo VK, Reardon DA, Fernandez S, Caligiuri M, Chiocca EA. Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Scientific Reports. 8: 208. PMID 29317703 DOI: 10.1038/S41598-017-18540-2 |
0.372 |
|
| 2018 |
Ahmed EH, Brooks E, Sloan S, Schlotter S, Jeney F, Mao C, Shindiapina P, Shire S, Hale C, Das M, Prouty A, Caligiuri MA, Baiocchi RA. BZLF1-DEC205 Fusion Protein Enhances EBV-Protective Immunity in a Spontaneous Model of EBV-Driven Lymphoproliferative Disease Blood. 132: 342-342. DOI: 10.1182/Blood-2018-99-117837 |
0.423 |
|
| 2018 |
Scoville SD, Nalin A, Chen L, Chen L, McConnell K, Casas SB, Al-Rahman A, Hashi N, Zhang M, Saultz J, Yu J, Freud A, Caligiuri M, Mundy-Bosse B. Abstract 4729: The aryl hydrocarbon receptor directly regulates microRNA-29b to inhibit human natural killer cell development and function in acute myeloid leukemia Cancer Research. 78: 4729-4729. DOI: 10.1158/1538-7445.Am2018-4729 |
0.72 |
|
| 2018 |
Ahmed EH, Hale C, Sloan S, Mao C, Zhang X, Ozer HG, Subramaniam D, Jeney F, Schlotter S, Smith P, Chan W, Sekhri P, Weigel C, Oakes CC, Behbehani GK, ... ... Caligiuri MA, et al. Abstract 4691: Role of select T helper cell subsets in the development of Epstein-Barr virus-driven lymphoproliferative disease Immunology. DOI: 10.1158/1538-7445.Am2018-4691 |
0.328 |
|
| 2018 |
Kartan S, Denlinger N, McLaughlin E, Chakravarti N, Huang S, Chen L, Mao H, Kline D, Youssef Y, Kohnken R, Young K, Lee D, Lozanski G, Freud A, Porcu P, ... ... Caligiuri M, et al. Enhanced Spontaneous Anti-Tumor Cytotoxicity of Natural Killer Cells in Cutaneous T-Cell Lymphoma Patients Clinical Lymphoma Myeloma and Leukemia. 18: S287-S288. DOI: 10.1016/J.Clml.2018.07.226 |
0.673 |
|
| 2017 |
Victor AR, Weigel C, Scoville SD, Chan WK, Chatman K, Nemer MM, Mao C, Young KA, Zhang J, Yu J, Freud AG, Oakes CC, Caligiuri MA. Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. Journal of Immunology (Baltimore, Md. : 1950). PMID 29229679 DOI: 10.4049/Jimmunol.1701128 |
0.715 |
|
| 2017 |
Kohnken R, Wen J, Mundy-Bosse B, McConnell K, Keiter A, Grinshpun L, Hartlage A, Yano M, McNeil B, Chakravarti N, William B, Bradner JE, Caligiuri MA, Porcu P, Mishra A. Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma. Blood. PMID 29180399 DOI: 10.1182/Blood-2017-09-805663 |
0.432 |
|
| 2017 |
Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The Broad Spectrum of Human Natural Killer Cell Diversity. Immunity. 47: 820-833. PMID 29166586 DOI: 10.1016/J.Immuni.2017.10.008 |
0.713 |
|
| 2017 |
Victor AR, Nalin AP, Dong W, McClory S, Wei M, Mao C, Kladney RD, Youssef Y, Chan WK, Briercheck EL, Hughes T, Scoville SD, Pitarresi JR, Chen C, Manz S, ... ... Caligiuri MA, et al. IL-18 Drives ILC3 Proliferation and Promotes IL-22 Production via NF-κB. Journal of Immunology (Baltimore, Md. : 1950). PMID 28842466 DOI: 10.4049/Jimmunol.1601554 |
0.8 |
|
| 2017 |
Campbell AR, Duggan MC, Suarez-Kelly LP, Bhave N, Opheim KS, McMichael E, Trikha P, Parihar R, Luedke E, Lewis A, Yung B, Lee R, Raulet D, Tridandapani S, Groh V, ... ... Caligiuri MA, et al. MICA-expressing monocytes enhance natural killer cell Fc receptor-mediated antitumor functions. Cancer Immunology Research. PMID 28724544 DOI: 10.1158/2326-6066.Cir-16-0005 |
0.498 |
|
| 2017 |
Dai HS, Griffin N, Bolyard C, Mao HC, Zhang J, Cripe TP, Suenaga T, Arase H, Nakano I, Chiocca EA, Kaur B, Yu J, Caligiuri MA. The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells. Immunity. 47: 159-170.e10. PMID 28723548 DOI: 10.1016/J.Immuni.2017.06.019 |
0.569 |
|
| 2017 |
Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, ... ... Caligiuri MA, et al. Ibrutinib treatment improves T cell number and function in CLL patients. The Journal of Clinical Investigation. PMID 28714866 DOI: 10.1172/Jci89756 |
0.378 |
|
| 2017 |
Papaioannou D, Shen C, Nicolet D, McNeil B, Bill M, Karunasiri M, Burke MH, Ozer HG, Yilmaz SA, Zitzer N, Behbehani GK, Oakes CC, Steiner DJ, Marcucci G, Powell BL, ... ... Caligiuri MA, et al. Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. PMID 28533390 DOI: 10.1073/Pnas.1703142114 |
0.693 |
|
| 2017 |
Chen L, Mao H, Zhang J, Chu J, Devine S, Caligiuri MA, Yu J. Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Leukemia. PMID 28496177 DOI: 10.1038/Leu.2017.147 |
0.349 |
|
| 2017 |
Scoville SD, Freud AG, Caligiuri MA. Modeling Human Natural Killer Cell Development in the Era of Innate Lymphoid Cells. Frontiers in Immunology. 8: 360. PMID 28396671 DOI: 10.3389/Fimmu.2017.00360 |
0.707 |
|
| 2017 |
Kohnken R, Wen J, Mundy-Bosse B, Yano M, Grinshpun L, McConnell K, Keiter A, Hartlage A, Bradner J, Caligiuri M, Porcu P, Mishra A. Abstract 481: Diminished microRNA-29b results in overexpression of BRD4 and BRD4-regulated oncogenes in cutaneous T-cell lymphoma Cancer Research. 77: 481-481. DOI: 10.1158/1538-7445.Am2017-481 |
0.356 |
|
| 2017 |
Wang Y, Zhang Y, Bnson D, Caligiuri M, Yu J. Abstract 4617: Daratumumab combined with CD38(-) natural killer cells armed with a CS1 chimeric antigen receptor for the treatment of relapsed multiple myeloma Cancer Research. 77: 4617-4617. DOI: 10.1158/1538-7445.Am2017-4617 |
0.468 |
|
| 2017 |
Xiao R, Bergin SM, Caligiuri MA, Cao L. Abstract 2817: Enriched environment inhibits progression of acute myeloid leukemia Cancer Research. 77: 2817-2817. DOI: 10.1158/1538-7445.Am2017-2817 |
0.358 |
|
| 2017 |
Deng T, Liu J, Deng Y, Minze L, Xiao X, Wright V, Yu R, Li XC, Blaszczak A, Bergin S, DiSilvestro D, Judd R, Bradley D, Caligiuri M, Lyon CJ, et al. Adipocyte adaptive immunity mediates diet-induced adipose inflammation and insulin resistance by decreasing adipose Treg cells Nature Communications. 8. DOI: 10.1038/Ncomms15725 |
0.316 |
|
| 2016 |
Teng KY, Han J, Zhang X, Hsu SH, He S, Wani N, Barajas J, Snyder LA, Frankel WL, Caligiuri MA, Jacob ST, Yu J, Ghoshal K. Blocking the Ccl2-Ccr2 axis using Ccl2 neutralizing antibody is an effective therapy for hepatocellular cancer in a mouse model. Molecular Cancer Therapeutics. PMID 27980102 DOI: 10.1158/1535-7163.Mct-16-0124 |
0.338 |
|
| 2016 |
Mace EM, Bigley V, Gunesch JT, Chinn IK, Angelo LS, Care MA, Maisuria S, Keller MD, Togi S, Watkin LB, LaRosa DF, Jhangiani SN, Muzny DM, Stray-Pedersen A, Coban Akdemir Z, ... ... Caligiuri MA, et al. Biallelic mutations in IRF8 impair human NK cell maturation and function. The Journal of Clinical Investigation. PMID 27893462 DOI: 10.1172/Jci86276 |
0.707 |
|
| 2016 |
Bolyard CM, Meisen WH, Banasavadi-Siddegowda Y, Hardcastle J, Yoo JY, Wohleb ES, Wojton J, Yu JG, Dubin S, Khosla M, Xu B, Smith JG, Alvarez-Breckenridge C, Pow-Anpongkul P, Pichiorri F, ... ... Caligiuri MA, et al. BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection- implications for Oncolytic Viral Therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27852701 DOI: 10.1158/1078-0432.Ccr-16-1818 |
0.467 |
|
| 2016 |
Mundy-Bosse BL, Scoville SD, Chen L, McConnell K, Mao HC, Ahmed EH, Zorko N, Harvey S, Cole J, Zhang X, Costinean S, Croce CM, Larkin K, Byrd JC, Vasu S, ... ... Caligiuri MA, et al. MicroRNA-29b mediates altered innate immune development in acute leukemia. The Journal of Clinical Investigation. PMID 27775550 DOI: 10.1172/Jci85413 |
0.724 |
|
| 2016 |
Trikha P, Plews RL, Stiff A, Gautam S, Hsu V, Abood D, Wesolowski R, Landi I, Mo X, Phay J, Chen CS, Byrd J, Caligiuri M, Tridandapani S, Carson W. Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator. Oncoimmunology. 5: e1214787. PMID 27757311 DOI: 10.1080/2162402X.2016.1214787 |
0.427 |
|
| 2016 |
Haverkos BM, Gru AA, Geyer SM, Bingman AK, Hemminger JA, Mishra A, Wong HK, Pancholi P, Freud AG, Caligiuri MA, Baiocchi RA, Porcu P. Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. 16: S181-S190.e4. PMID 27521316 DOI: 10.1016/J.Clml.2016.02.014 |
0.625 |
|
| 2016 |
Mishra A, La Perle K, Kwiatkowski S, Sullivan LA, Sams GH, Johns J, Curphey DP, Wen J, McConnell K, Qi J, Wong H, Russo G, Zhang J, Marcucci G, Bradner JE, ... ... Caligiuri MA, et al. Mechanism, consequences and therapeutic targeting of abnormal IL-15 signaling in cutaneous T-cell lymphoma. Cancer Discovery. PMID 27422033 DOI: 10.1158/2159-8290.Cd-15-1297 |
0.435 |
|
| 2016 |
Yoo JY, Jaime-Ramirez AC, Bolyard C, Dai H, Nallanagulagari T, Wojton J, Hurwitz B, Relation T, Yu JG, Lee TJ, Lotze MT, Zhang J, Croce CM, Yu J, Caligiuri MA, et al. Bortezomib treatment sensitizes oncolytic HSV-1 treated tumors to NK cell immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27390350 DOI: 10.1158/1078-0432.Ccr-16-1003 |
0.581 |
|
| 2016 |
Freud AG, Keller KA, Scoville SD, Mundy-Bosse BL, Cheng S, Youssef Y, Hughes T, Zhang X, Mo X, Porcu P, Baiocchi RA, Yu J, Carson WE, Caligiuri MA. NKp80 Defines a Critical Step during Human Natural Killer Cell Development. Cell Reports. PMID 27373165 DOI: 10.1016/J.Celrep.2016.05.095 |
0.687 |
|
| 2016 |
Scoville SD, Mundy-Bosse BL, Zhang MH, Chen L, Zhang X, Keller KA, Hughes T, Chen L, Cheng S, Bergin SM, Mao HC, McClory S, Yu J, Carson WE, Caligiuri MA, et al. A Progenitor Cell Expressing Transcription Factor RORγt Generates All Human Innate Lymphoid Cell Subsets. Immunity. PMID 27178467 DOI: 10.1016/J.Immuni.2016.04.007 |
0.817 |
|
| 2016 |
Xiao R, Bergin SM, Huang W, Slater AM, Liu X, Judd RT, Lin ED, Widstrom KJ, Scoville SD, Yu J, Caligiuri M, Cao L. Environmental and genetic activation of hypothalamic BDNF modulates T-cell immunity to exert an anticancer phenotype. Cancer Immunology Research. PMID 27045020 DOI: 10.1158/2326-6066.Cir-15-0297 |
0.382 |
|
| 2016 |
Vasu S, He S, Cheney C, Gopalakrishnan B, Mani R, Lozanski G, Mo X, Groh V, Whitman SP, Konopitzky R, Kössl C, Bucci D, Lucas DM, Yu J, Caligiuri MA, et al. Decitabine enhances Fc engineered anti-CD33 mAb mediated natural killer antibody dependent cellular cytotoxicity against AML blasts. Blood. PMID 27013443 DOI: 10.1182/Blood-2015-11-680546 |
0.402 |
|
| 2016 |
Stiff A, Trikha P, Wesolowski R, Kendra K, Hsu V, Uppati S, McMichael EL, Duggan M, Campbell A, Keller K, Landi I, Zhong Y, Dubovsky J, Howard JH, Yu L, ... ... Caligiuri M, et al. Myeloid-derived suppressor cells express Bruton's tyrosine kinase and can be depleted in tumor bearing hosts by ibrutinib treatment. Cancer Research. PMID 26880800 DOI: 10.1158/0008-5472.Can-15-1490 |
0.443 |
|
| 2016 |
Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, LaPerle KM, Schmitt AC, ... ... Caligiuri M, et al. NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin are Enhanced by Cytokines. Cancer Immunology Research. PMID 26865456 DOI: 10.1158/2326-6066.Cir-15-0168 |
0.497 |
|
| 2016 |
Mims AS, Klisovic RB, Garzon R, Walker AR, Devine SM, Walsh KJ, Vasu S, Whitman SP, Marcucci G, Heerema NA, Caligiuri MA, Bloomfield CD, Byrd JC, Piekarz R, Grever MR, et al. A Novel Regimen for Acute Myeloid Leukemia with MLL Partial Tandem Duplication: Results of a Phase 1 Study NCI 8485 Blood. 128: 900-900. DOI: 10.1182/Blood.V128.22.900.900 |
0.302 |
|
| 2016 |
Long M, Beckwith KA, Do P, Bethany ML, Gordon G, Lehman AM, Maddocks KJ, Cheney C, Jones J, Andritsos LA, Awan FT, Fraietta JA, June CH, Maus MV, Woyach JA, ... Caligiuri MA, et al. Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism Blood. 128: 3238-3238. DOI: 10.1182/Blood.V128.22.3238.3238 |
0.449 |
|
| 2016 |
Yu J, Silvestri G, Stramucci L, Sanada M, Yamaguchi T, Du Y, Westermarck J, Caligiuri MA, Garzon R, Milojkovic D, Apperley JF, Roy D, Marcucci G, Calabretta B, Baer MR, et al. Potential Targeting Ph+ Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity Blood. 128: 2909-2909. DOI: 10.1182/Blood.V128.22.2909.2909 |
0.37 |
|
| 2016 |
Shen C, Papaioannou D, Mcneil B, Nicolet D, Karunasiri M, Burke M, Nina Z, Behbehani GK, Ozer HG, Yilmaz S, Marcucci G, Caligiuri MA, Bloomfield CD, Garzon R, Dorrance A. EGFL7 Antagonizes NOTCH Signaling, Stimulates Blast Proliferation and Confers Poor Prognosis in Cytogenetically-Normal Acute Myeloid Leukemia (CN-AML) Blood. 128: 2689-2689. DOI: 10.1182/Blood.V128.22.2689.2689 |
0.707 |
|
| 2016 |
Kohnken R, Wen J, Yano M, Hartlage A, Grinshpun L, Caligiuri MA, Porcu P, Mishra A. Targeting BRD4 Disables IL-15 Oncogenic Signaling in Cutaneous T-Cell Lymphoma Via Down Regulation of IL-15 Receptor Complex Blood. 128: 1097-1097. DOI: 10.1182/Blood.V128.22.1097.1097 |
0.488 |
|
| 2015 |
Han J, Chen X, Chu J, Xu B, Meisen WH, Chen L, Zhang L, Zhang J, He X, Wang QE, Chiocca EA, Kaur B, Caligiuri MA, Yu J. TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. Cancer Research. PMID 26631269 DOI: 10.1158/0008-5472.Can-15-0894 |
0.603 |
|
| 2015 |
Tarighat SS, Santhanam R, Frankhouser D, Radomska HS, Lai H, Anghelina M, Wang H, Huang X, Alinari L, Walker A, Caligiuri MA, Croce CM, Li L, Garzon R, Li C, et al. The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation. Leukemia. PMID 26536822 DOI: 10.1038/Leu.2015.308 |
0.352 |
|
| 2015 |
Martin del Campo SE, Levine KM, Mundy-Bosse BL, Grignol VP, Fairchild ET, Campbell AR, Trikha P, Mace TA, Paul BK, Jaime-Ramirez AC, Markowitz J, Kondadasula SV, Guenterberg KD, McClory S, Karpa VI, ... ... Caligiuri MA, et al. The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells. Journal of Immunology (Baltimore, Md. : 1950). 195: 1995-2005. PMID 26238487 DOI: 10.4049/Jimmunol.1400084 |
0.816 |
|
| 2015 |
Scoville SD, Keller KA, Cheng S, Zhang M, Zhang X, Caligiuri MA, Freud AG. Rapid Column-Free Enrichment of Mononuclear Cells from Solid Tissues. Scientific Reports. 5: 12490. PMID 26223896 DOI: 10.1038/Srep12490 |
0.62 |
|
| 2015 |
Han J, Chu J, Keung Chan W, Zhang J, Wang Y, Cohen JB, Victor A, Meisen WH, Kim SH, Grandi P, Wang QE, He X, Nakano I, Chiocca EA, Glorioso Iii JC, ... ... Caligiuri MA, et al. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. Scientific Reports. 5: 11483. PMID 26155832 DOI: 10.1038/Srep11483 |
0.617 |
|
| 2015 |
Dorrance AM, Neviani P, Ferenchak GJ, Huang X, Nicolet D, Maharry KS, Ozer HG, Hoellarbauer P, Khalife J, Hill EB, Yadav M, Bolon BN, Lee RJ, Lee LJ, Croce CM, ... ... Caligiuri MA, et al. Targeting leukemia stem cells in vivo with ANTAGOMIR-126 nanoparticles in acute myeloid leukemia. Leukemia. PMID 26055302 DOI: 10.1038/Leu.2015.139 |
0.673 |
|
| 2015 |
Benson DM, Cohen AD, Jagannath S, Munshi NC, Spitzer G, Hofmeister CC, Efebera YA, Andre P, Zerbib R, Caligiuri MA. A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 25999435 DOI: 10.1158/1078-0432.Ccr-15-0304 |
0.407 |
|
| 2015 |
Meisen WH, Wohleb ES, Jaime-Ramirez AC, Bolyard C, Yoo JY, Russell L, Hardcastle J, Dubin S, Muili K, Yu J, Caligiuri M, Godbout J, Kaur B. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3274-85. PMID 25829396 DOI: 10.1158/1078-0432.Ccr-14-3118 |
0.487 |
|
| 2015 |
Wong HK, Gibson H, Hake T, Geyer S, Frederickson J, Marcucci G, Caligiuri MA, Porcu P, Mishra A. Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3, GATA6, and TWIST1 in the Sezary Syndrome. The Journal of Investigative Dermatology. 135: 2084-92. PMID 25806852 DOI: 10.1038/Jid.2015.116 |
0.412 |
|
| 2015 |
Ozer HG, Usubalieva A, Dorrance A, Yilmaz AS, Caligiuri M, Marcucci G, Huang K. Identification of medium-sized copy number alterations in whole-genome sequencing. Cancer Informatics. 13: 105-11. PMID 25788829 DOI: 10.4137/Cin.S14023 |
0.625 |
|
| 2015 |
Deng Y, Kerdiles Y, Chu J, Yuan S, Wang Y, Chen X, Mao H, Zhang L, Zhang J, Hughes T, Deng Y, Zhang Q, Wang F, Zou X, Liu CG, ... ... Caligiuri MA, et al. Transcription factor Foxo1 is a negative regulator of natural killer cell maturation and function. Immunity. 42: 457-70. PMID 25769609 DOI: 10.1016/J.Immuni.2015.02.006 |
0.702 |
|
| 2015 |
Hartlage AS, Liu T, Patton JT, Garman SL, Zhang X, Kurt H, Lozanski G, Lustberg ME, Caligiuri MA, Baiocchi RA. The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development. Cancer Immunology Research. 3: 787-94. PMID 25735952 DOI: 10.1182/Blood.V124.21.4144.4144 |
0.363 |
|
| 2015 |
Elavazhagan S, Fatehchand K, Santhanam V, Fang H, Ren L, Gautam S, Reader B, Mo X, Cheney C, Briercheck E, Vasilakos JP, Dietsch GN, Hershberg RM, Caligiuri M, Byrd JC, et al. Granzyme B expression is enhanced in human monocytes by TLR8 agonists and contributes to antibody-dependent cellular cytotoxicity. Journal of Immunology (Baltimore, Md. : 1950). 194: 2786-95. PMID 25667415 DOI: 10.4049/Jimmunol.1402316 |
0.78 |
|
| 2015 |
Kühn MW, Hadler MJ, Daigle SR, Koche RP, Krivtsov AV, Olhava EJ, Caligiuri MA, Huang G, Bradner JE, Pollock RM, Armstrong SA. MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition. Haematologica. 100: e190-3. PMID 25596271 DOI: 10.3324/Haematol.2014.115337 |
0.361 |
|
| 2015 |
Briercheck EL, Trotta R, Chen L, Hartlage AS, Cole JP, Cole TD, Mao C, Banerjee PP, Hsu HT, Mace EM, Ciarlariello D, Mundy-Bosse BL, Garcia-Cao I, Scoville SD, Yu L, ... ... Caligiuri MA, et al. PTEN is a negative regulator of NK cell cytolytic function. Journal of Immunology (Baltimore, Md. : 1950). 194: 1832-40. PMID 25595786 DOI: 10.4049/Jimmunol.1401224 |
0.827 |
|
| 2015 |
Mazzacurati L, Marzulli M, Reinhart B, Miyagawa Y, Uchida H, Goins WF, Li A, Kaur B, Caligiuri M, Cripe T, Chiocca EA, Chiocca N, Amankulor N, Cohen JB, Glorioso JC, et al. Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 99-107. PMID 25200130 DOI: 10.1038/Mt.2014.177 |
0.504 |
|
| 2015 |
Mishra A, Hartlage A, Sullivan L, Grinshpun L, Kwiatkowski S, Qi J, Bradner JE, Porcu P, Caligiuri MA. Genome-Wide Mapping Reveals BRD4 in Regulation of Tumor-Driver Genes in Cutaneous T-Cell Lymphoma Blood. 126: 589-589. DOI: 10.1182/Blood.V126.23.589.589 |
0.427 |
|
| 2015 |
Mishra A, Kwiatkowski S, Sullivan L, Grinshpun L, Russo G, Porcu P, Caligiuri MA. Epigenetic Disruption of ZEB1 Binding Causes Constitutive Activation of IL-15 in Cutaneous T-Cell Lymphoma Blood. 126: 3635-3635. DOI: 10.1182/Blood.V126.23.3635.3635 |
0.427 |
|
| 2015 |
Hayashi Y, Zhang Y, Yan X, Choi K, Sashida G, Dong Y, Xu Z, Wu L, Chen A, Sun X, Olsson A, Harada H, Shih L, Tse W, Bridges J, ... ... Caligiuri MA, et al. HIF-1a Pathway, As a Signal Funnel for Genetic, Epigenetic, and Metabolic Aberrations, Is Sufficient and Essential for MDS Development Blood. 126: 303-303. DOI: 10.1182/Blood.V126.23.303.303 |
0.339 |
|
| 2015 |
Xilin C, Han J, Jianhong C, Meisen W, Jianying Z, Chiocca EA, Kaur B, Caligiuri MA, Yu J. Modulation of Natural Killer Cell Activity in the Setting of Oncolytic Virotherapy and with a Chimeric Antigen Receptor Blood. 126: 210-210. DOI: 10.1182/Blood.V126.23.210.210 |
0.615 |
|
| 2015 |
Scoville S, Mundy-Bosse B, Zhang M, Chen L, Sanderson R, Hughes T, Garzon R, Mishra A, Costinean S, Croce CM, Freud AG, Caligiuri MA. Microrna 29b Mediates Immune Evasion of Natural Killer Cells in Acute Myeloid Leukemia Blood. 126: 207-207. DOI: 10.1182/Blood.V126.23.207.207 |
0.715 |
|
| 2015 |
Chen L, Yi L, Ren Y, Zhang J, Kinghorn AD, Caligiuri MA, Yu J. Enhancement of Natural Killer Cell Interferon-Gamma Production By the Derivatives of the Natural Product Phyllanthusmins Via TLR-Mediated NF-Kb and STAT3 Signaling Pathways Blood. 126: 1031-1031. DOI: 10.1182/Blood.V126.23.1031.1031 |
0.442 |
|
| 2014 |
Deng Y, Chu J, Ren Y, Fan Z, Ji X, Mundy-Bosse B, Yuan S, Hughes T, Zhang J, Cheema B, Camardo AT, Xia Y, Wu LC, Wang LS, He X, ... ... Caligiuri MA, et al. The natural product phyllanthusmin C enhances IFN-γ production by human NK cells through upregulation of TLR-mediated NF-κB signaling. Journal of Immunology (Baltimore, Md. : 1950). 193: 2994-3002. PMID 25122922 DOI: 10.4049/Jimmunol.1302600 |
0.45 |
|
| 2014 |
Wang Y, Liu Y, Tang F, Bernot KM, Schore R, Marcucci G, Caligiuri MA, Zheng P, Liu Y. Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells. Blood. 124: 1127-35. PMID 24994068 DOI: 10.1182/Blood-2013-12-544221 |
0.373 |
|
| 2014 |
Hughes T, Briercheck EL, Freud AG, Trotta R, McClory S, Scoville SD, Keller K, Deng Y, Cole J, Harrison N, Mao C, Zhang J, Benson DM, Yu J, Caligiuri MA. The transcription Factor AHR prevents the differentiation of a stage 3 innate lymphoid cell subset to natural killer cells. Cell Reports. 8: 150-62. PMID 24953655 DOI: 10.1016/J.Celrep.2014.05.042 |
0.833 |
|
| 2014 |
Thorne AH, Meisen WH, Russell L, Yoo JY, Bolyard CM, Lathia JD, Rich J, Puduvalli VK, Mao H, Yu J, Caligiuri MA, Tridandapani S, Kaur B. Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1678-87. PMID 24895995 DOI: 10.1038/Mt.2014.101 |
0.565 |
|
| 2014 |
Yoo JY, Hurwitz BS, Bolyard C, Yu JG, Zhang J, Selvendiran K, Rath KS, He S, Bailey Z, Eaves D, Cripe TP, Parris DS, Caligiuri MA, Yu J, Old M, et al. Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3787-98. PMID 24815720 DOI: 10.1158/1078-0432.Ccr-14-0553 |
0.479 |
|
| 2014 |
Mishra A, Sullivan L, Caligiuri MA. Molecular pathways: interleukin-15 signaling in health and in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2044-50. PMID 24737791 DOI: 10.1158/1078-0432.Ccr-12-3603 |
0.422 |
|
| 2014 |
Freud AG, Yu J, Caligiuri MA. Human natural killer cell development in secondary lymphoid tissues. Seminars in Immunology. 26: 132-7. PMID 24661538 DOI: 10.1016/J.Smim.2014.02.008 |
0.689 |
|
| 2014 |
Benson DM, Caligiuri MA. Killer immunoglobulin-like receptors and tumor immunity. Cancer Immunology Research. 2: 99-104. PMID 24592397 DOI: 10.1158/2326-6066.Cir-13-0219 |
0.458 |
|
| 2014 |
Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Tarighat SS, Volinia S, ... ... Caligiuri MA, et al. SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. The Journal of Clinical Investigation. 124: 1512-24. PMID 24590286 DOI: 10.1172/Jci70921 |
0.704 |
|
| 2014 |
Kolitz JE, George SL, Benson DM, Maharry K, Marcucci G, Vij R, Powell BL, Allen SL, Deangelo DJ, Shea TC, Stock W, Bakan CE, Hars V, Hoke E, Bloomfield CD, ... Caligiuri MA, et al. Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer. 120: 1010-7. PMID 24382782 DOI: 10.1002/Cncr.28516 |
0.366 |
|
| 2014 |
Whitman SP, Kohlschmidt J, Maharry K, Volinia S, Mrózek K, Nicolet D, Schwind S, Becker H, Metzeler KH, Mendler JH, Eisfeld AK, Carroll AJ, Powell BL, Carter TH, Baer MR, ... ... Caligiuri MA, et al. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Leukemia. 28: 1252-8. PMID 24326683 DOI: 10.1038/Leu.2013.371 |
0.337 |
|
| 2014 |
Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He X, Devine SM, Zhang X, Caligiuri MA, Hofmeister CC, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 28: 917-27. PMID 24067492 DOI: 10.1038/Leu.2013.279 |
0.471 |
|
| 2014 |
Mundy-Bosse B, Kathleen M, Mao C, Ahmed E, Chen L, Scoville SD, Freud AG, Yu J, Caligiuri MA. Acute Myeloid Leukemia Alters Natural Killer Cell Maturation and Functional Activation Blood. 124: 754-754. DOI: 10.1182/Blood.V124.21.754.754 |
0.723 |
|
| 2014 |
Scoville SD, Keller K, Mundy-Bosse B, Caligiuri MA, Freud AG. A Novel CD94+ Immature NK Cell Population Based on NKp80 Expression with ILC3-like Features in Human Secondary Lymphoid Tissue Blood. 124: 751-751. DOI: 10.1182/Blood.V124.21.751.751 |
0.723 |
|
| 2014 |
Park I, Mundy-Bosse B, Warner SL, Bearss DJ, Marcucci G, Caligiuri MA. The Receptor Tyrosine Kinase Axl Is Required for Resistance to FLT3-Targeted Therapy in Acute Myeloid Leukemia Blood. 124: 2350-2350. DOI: 10.1182/Blood.V124.21.2350.2350 |
0.355 |
|
| 2014 |
Dugan J, Haverkos BM, Martin LK, Martin MF, Lustberg ME, Patton JT, Nuovo G, Yan F, Cavaliere R, Kenney SC, Fingeroth J, Lozanski G, Ramos JC, Porcu P, Caligiuri MA, et al. Epstein-Barr Virus Kinase-Targeted Therapy for Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder Blood. 124: 1750-1750. DOI: 10.1182/Blood.V124.21.1750.1750 |
0.331 |
|
| 2013 |
Bernot KM, Nemer JS, Santhanam R, Liu S, Zorko NA, Whitman SP, Dickerson KE, Zhang M, Yang X, McConnell KK, Ahmed EH, Muñoz MR, Siebenaler RF, Marcucci GG, Mundy-Bosse BL, ... ... Caligiuri MA, et al. Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease. Blood. 122: 3778-83. PMID 24085765 DOI: 10.1182/Blood-2013-06-507426 |
0.684 |
|
| 2013 |
Yu J, Freud AG, Caligiuri MA. Location and cellular stages of natural killer cell development. Trends in Immunology. 34: 573-82. PMID 24055329 DOI: 10.1016/J.It.2013.07.005 |
0.701 |
|
| 2013 |
Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, ... ... Caligiuri MA, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. The Journal of Clinical Investigation. 123: 4144-57. PMID 23999433 DOI: 10.1172/Jci68951 |
0.672 |
|
| 2013 |
Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P, Roy DC, Reid A, et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood. 122: 3034-44. PMID 23970380 DOI: 10.1182/Blood-2013-04-495374 |
0.385 |
|
| 2013 |
Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, Abdel-Wahab O, Levine R, et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 122: 1923-34. PMID 23926298 DOI: 10.1182/Blood-2013-03-492181 |
0.359 |
|
| 2013 |
Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, ... ... Caligiuri MA, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 122: 2539-49. PMID 23886836 DOI: 10.1182/Blood-2013-06-507947 |
0.352 |
|
| 2013 |
Alvarez-Breckenridge CA, Yu J, Caligiuri MA, Chiocca EA. Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy. Oncoimmunology. 2: e23658. PMID 23734319 DOI: 10.4161/Onci.23658 |
0.381 |
|
| 2013 |
Park IK, Trotta R, Yu J, Caligiuri MA. Axl/Gas6 pathway positively regulates FLT3 activation in human natural killer cell development. European Journal of Immunology. 43: 2750-5. PMID 23722894 DOI: 10.1002/Eji.201243116 |
0.511 |
|
| 2013 |
Harb JG, Neviani P, Chyla BJ, Ellis JJ, Ferenchak GJ, Oaks JJ, Walker CJ, Hokland P, Roy DC, Caligiuri MA, Marcucci G, Huettner CS, Perrotti D. Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target. Leukemia. 27: 1996-2005. PMID 23670294 DOI: 10.1038/Leu.2013.151 |
0.397 |
|
| 2013 |
Bernot KM, Siebenaler RF, Whitman SP, Zorko NA, Marcucci GG, Santhanam R, Ahmed EH, Ngangana M, McConnell KK, Nemer JS, Brook DL, Kulp SK, Chen CS, Frankhouser D, Yan P, ... ... Caligiuri MA, et al. Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML. Leukemia. 27: 2379-82. PMID 23660685 DOI: 10.1038/Leu.2013.147 |
0.646 |
|
| 2013 |
He S, Chu J, Wu LC, Mao H, Peng Y, Alvarez-Breckenridge CA, Hughes T, Wei M, Zhang J, Yuan S, Sandhu S, Vasu S, Benson DM, Hofmeister CC, He X, ... ... Caligiuri MA, et al. MicroRNAs activate natural killer cells through Toll-like receptor signaling. Blood. 121: 4663-71. PMID 23580661 DOI: 10.1182/Blood-2012-07-441360 |
0.352 |
|
| 2013 |
Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. Journal of Hematology & Oncology. 6: 21. PMID 23497456 DOI: 10.1186/1756-8722-6-21 |
0.352 |
|
| 2013 |
Trotta R, Chen L, Costinean S, Josyula S, Mundy-Bosse BL, Ciarlariello D, Mao C, Briercheck EL, McConnell KK, Mishra A, Yu L, Croce CM, Caligiuri MA. Overexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells. Blood. 121: 3126-34. PMID 23422749 DOI: 10.1182/Blood-2012-12-467597 |
0.806 |
|
| 2013 |
Rafiq S, Butchar JP, Cheney C, Mo X, Trotta R, Caligiuri M, Jarjoura D, Tridandapani S, Muthusamy N, Byrd JC. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. Journal of Immunology (Baltimore, Md. : 1950). 190: 2702-11. PMID 23418626 DOI: 10.4049/Jimmunol.1202588 |
0.426 |
|
| 2013 |
Park IK, Mishra A, Chandler J, Whitman SP, Marcucci G, Caligiuri MA. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. Blood. 121: 2064-73. PMID 23321254 DOI: 10.1182/Blood-2012-07-444018 |
0.361 |
|
| 2013 |
Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, et al. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia. 27: 871-8. PMID 23178755 DOI: 10.1038/Leu.2012.342 |
0.663 |
|
| 2013 |
Schwind S, Edwards CG, Nicolet D, Mrózek K, Maharry K, Wu YZ, Paschka P, Eisfeld AK, Hoellerbauer P, Becker H, Metzeler KH, Curfman J, Kohlschmidt J, Prior TW, Kolitz JE, ... ... Caligiuri MA, et al. inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. Blood. 121: 385-91. PMID 23160462 DOI: 10.1182/Blood-2012-07-442772 |
0.317 |
|
| 2013 |
Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrózek K, Walker A, Eiring AM, Whitman SP, Becker H, ... ... Caligiuri MA, et al. Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood. 121: 159-69. PMID 23100311 DOI: 10.1182/Blood-2012-05-428573 |
0.659 |
|
| 2013 |
Hartlage AS, Pan L, Lustberg ME, Drohan CM, Martin MF, Kinghorn AD, Caligiuri MA, Grever MR, Lucas DM, Baiocchi RA. Silvestrol Modulates Indirect Anti-Tumor Activity and Potentiates Immune Response To Epstein-Barr Virus-Driven Lymphoproliferative Disease Blood. 122: 4422-4422. DOI: 10.1182/Blood.V122.21.4422.4422 |
0.439 |
|
| 2013 |
Wang H, Santhanam R, Xie Z, Huang X, Chiu M, Phelps MA, Walker AR, Caligiuri MA, Garzon R, Lee J, Muthusamy N, Chan KK, Marcucci G. A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2’-O-Methylphosphorothioate Mir-29b Blood. 122: 3933-3933. DOI: 10.1182/Blood.V122.21.3933.3933 |
0.309 |
|
| 2013 |
Khalife JC, Radomska HS, Saultz J, Santhanam R, Huang X, Wang H, Curfman JP, Wu Y, Hoellerbauer P, Alachkar H, Dorrance AM, Caligiuri MA, Garzon R, Mendler JH, Marcucci G. Targeting Mir-155 via The NEDD8-Activating Enzyme Inhibitor MLN4924: A Novel Therapeutic Approach For Acute Myeloid Leukemia (AML) Blood. 122: 3804-3804. DOI: 10.1182/Blood.V122.21.3804.3804 |
0.689 |
|
| 2013 |
Benson DM, Cohen AD, Hofmeister CC, Nikhil MC, Jagannath S, Efebera YA, Spitzer G, Zerbib R, Andre P, Oxier S, Caligiuri MA. A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma Blood. 122: 3181-3181. DOI: 10.1182/Blood.V122.21.3181.3181 |
0.332 |
|
| 2013 |
Mishra A, La Perle KM, Sullivan L, Sams GH, Curphey DP, McConnell K, Qi J, Wong HK, Kulp SK, Fernandez S, Bradner JE, Marcucci G, Chen C, Porcu P, Caligiuri MA. Increased Expression Of IL-15 Promotes Cutaneous T-Cell Lymphomagenesis Via The Upregulation Of Histone Deacetylases: Evidence For Successful Preclinical Targeting Blood. 122: 1826-1826. DOI: 10.1182/Blood.V122.21.1826.1826 |
0.449 |
|
| 2013 |
Chu J, Deng Y, Benson DM, He S, Hughes TL, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He X, Devine SM, Zhang X, Caligiuri MA, Hofmeister CC, et al. CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered NK Cells and T Cells Enhance In Vitro and In Vivo Anti-Tumor Activity Against Human Multiple Myeloma Blood. 122: 14-14. DOI: 10.1182/Blood.V122.21.14.14 |
0.474 |
|
| 2013 |
Kühn MW, Hadler M, Daigle SR, Chen C, Sinha AU, Krivtsov AV, Olhava EJ, Caligiuri MA, Bradner JE, Pollock RM, Armstrong SA. Myeloid Leukemia Cells With MLL partial Tandem Duplication Are Sensitive To Pharmacological Inhibition Of The H3K79 Methyltransferase DOT1L Blood. 122: 1256-1256. DOI: 10.1182/Blood.V122.21.1256.1256 |
0.423 |
|
| 2013 |
Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Hessler J, Liu T, Chang BY, Larkin KM, Stefanovski MR, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, ... ... Caligiuri MA, et al. Abstract 492: Ibrutinib inhibits Interleukin-2 inducible kinase, driving a Th1 selective pressure in human leukemia patients that serves to alleviate tumor-induced immunosupression. Cancer Research. 73: 492-492. DOI: 10.1158/1538-7445.Am2013-492 |
0.423 |
|
| 2013 |
Mishra A, Sullivan L, Sams G, Johns J, Curphey D, Falkenberg L, Gibson H, Liu S, Jaroncyk L, McConnell K, Wong H, Perle KL, Garzon R, Marcucci G, Porcu P, ... Caligiuri M, et al. Abstract 3857: Targeting HDAC1 in a novel model of cutaneous T-cell lymphoma. Cancer Research. 73: 3857-3857. DOI: 10.1158/1538-7445.Am2013-3857 |
0.472 |
|
| 2013 |
Zhang Y, Yan X, Sashida G, Chen A, Zhao X, Whitman SP, Caligiuri MA, Xiao Z, Grimes HL, Huang G. Abstract 3855: Modeling MLL-PTD related Myelodysplastic Syndromes (MDS) in mouse. Cancer Research. 73: 3855-3855. DOI: 10.1158/1538-7445.Am2013-3855 |
0.357 |
|
| 2013 |
Zorko NA, Yanes DA, Lewis WC, Brook DL, Bernot KM, Siebenaler RF, Whitman SP, Ahmed EH, McConnell KK, Nemer J, Ernst P, Huang G, Marcucci G, Caligiuri MA. Abstract 3849: The partial tandem duplication of Mll (Mll PTD) is a gain-of-function in the absence of Mll wildtype (Mll WT) in adult mouse hematopoiesis. Cancer Research. 73: 3849-3849. DOI: 10.1158/1538-7445.Am2013-3849 |
0.343 |
|
| 2013 |
Bernot KM, Nemer JS, Santhanam R, Liu S, Marcucci GG, Zorko NA, Whitman SP, Yan P, Frankhouser D, Bundschuh R, Zhang M, Siebenaler RF, Ahmed EH, McConnell KK, Munoz M, ... ... Caligiuri MA, et al. Abstract 3249: Targeting the miR29b/Sp1/Dnmt pathway for curative therapy in Mll-PTD/Flt3-ITD acute myeloid leukemia. Cancer Research. 73: 3249-3249. DOI: 10.1158/1538-7445.Am2013-3249 |
0.694 |
|
| 2013 |
Tarighat SS, Mahasenan K, Perrotti D, Garzon R, Caligiuri M, Li C, Blum W, Marcucci G, Baiocchi RA. Abstract 1128: Preclinical and pharmacological activities of protein arginine methyltransferase 5(PRMT5) enzyme inhibition in acute myeloid leukemia . Cancer Research. 73: 1128-1128. DOI: 10.1158/1538-7445.Am2013-1128 |
0.4 |
|
| 2012 |
Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H, Wei M, Wang Y, He S, Hardcastle J, Fernandez SA, Kaur B, Lawler SE, Vivier E, Mandelboim O, ... ... Caligiuri MA, et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nature Medicine. 18: 1827-34. PMID 23178246 DOI: 10.1038/Nm.3013 |
0.62 |
|
| 2012 |
Mishra A, Liu S, Sams GH, Curphey DP, Santhanam R, Rush LJ, Schaefer D, Falkenberg LG, Sullivan L, Jaroncyk L, Yang X, Fisk H, Wu LC, Hickey C, Chandler JC, ... ... Caligiuri MA, et al. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell. 22: 645-55. PMID 23153537 DOI: 10.1016/J.Ccr.2012.09.009 |
0.722 |
|
| 2012 |
Benson DM, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, Bakan C, Andre P, Efebera Y, Tiollier J, Caligiuri MA, Farag SS. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood. 120: 4324-33. PMID 23033266 DOI: 10.1182/Blood-2012-06-438028 |
0.345 |
|
| 2012 |
Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, ... ... Caligiuri MA, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3109-18. PMID 22753902 DOI: 10.1200/Jco.2011.40.6652 |
0.302 |
|
| 2012 |
Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, Lovat F, Fadda P, Mao C, Nuovo GJ, Zanesi N, Crawford M, Ozer GH, Wernicke D, Alder H, ... Caligiuri MA, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proceedings of the National Academy of Sciences of the United States of America. 109: E2110-6. PMID 22753494 DOI: 10.1073/Pnas.1209414109 |
0.314 |
|
| 2012 |
Zhang Y, Yan X, Sashida G, Zhao X, Rao Y, Goyama S, Whitman SP, Zorko N, Bernot K, Conway RM, Witte D, Wang QF, Tenen DG, Xiao Z, Marcucci G, ... ... Caligiuri MA, et al. Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells. Blood. 120: 1118-29. PMID 22740449 DOI: 10.1182/Blood-2012-02-412379 |
0.351 |
|
| 2012 |
Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, Klisovic R, Blum W, Caligiuri M, Croce CM, Marcucci G, Garzon R. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 120: 1765-73. PMID 22677130 DOI: 10.1182/Blood-2012-04-423160 |
0.39 |
|
| 2012 |
Zorko NA, Bernot KM, Whitman SP, Siebenaler RF, Ahmed EH, Marcucci GG, Yanes DA, McConnell KK, Mao C, Kalu C, Zhang X, Jarjoura D, Dorrance AM, Heerema NA, Lee BH, ... ... Caligiuri MA, et al. Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. Blood. 120: 1130-6. PMID 22674806 DOI: 10.1182/Blood-2012-03-415067 |
0.679 |
|
| 2012 |
Blum W, Schwind S, Tarighat SS, Geyer S, Eisfeld AK, Whitman S, Walker A, Klisovic R, Byrd JC, Santhanam R, Wang H, Curfman JP, Devine SM, Jacob S, Garr C, ... ... Caligiuri MA, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood. 119: 6025-31. PMID 22566605 DOI: 10.1182/Blood-2012-03-413898 |
0.333 |
|
| 2012 |
Ranganathan P, Heaphy CE, Costinean S, Stauffer N, Na C, Hamadani M, Santhanam R, Mao C, Taylor PA, Sandhu S, He G, Shana'ah A, Nuovo GJ, Lagana A, Cascione L, ... ... Caligiuri M, et al. Regulation of acute graft-versus-host disease by microRNA-155. Blood. 119: 4786-97. PMID 22408260 DOI: 10.1182/Blood-2011-10-387522 |
0.302 |
|
| 2012 |
Trotta R, Chen L, Ciarlariello D, Josyula S, Mao C, Costinean S, Yu L, Butchar JP, Tridandapani S, Croce CM, Caligiuri MA. miR-155 regulates IFN-γ production in natural killer cells. Blood. 119: 3478-85. PMID 22378844 DOI: 10.1182/Blood-2011-12-398099 |
0.434 |
|
| 2012 |
McClory S, Hughes T, Freud AG, Briercheck EL, Martin C, Trimboli AJ, Yu J, Zhang X, Leone G, Nuovo G, Caligiuri MA. Evidence for a stepwise program of extrathymic T cell development within the human tonsil. The Journal of Clinical Investigation. 122: 1403-15. PMID 22378041 DOI: 10.1172/Jci46125 |
0.805 |
|
| 2012 |
Alvarez-Breckenridge CA, Yu J, Price R, Wei M, Wang Y, Nowicki MO, Ha YP, Bergin S, Hwang C, Fernandez SA, Kaur B, Caligiuri MA, Chiocca EA. The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon. Journal of Virology. 86: 4566-77. PMID 22318143 DOI: 10.1128/Jvi.05545-11 |
0.612 |
|
| 2012 |
Alvarez-Breckenridge CA, Yu J, Kaur B, Caligiuri MA, Chiocca EA. Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells. Advances in Virology. 2012: 702839. PMID 22312364 DOI: 10.1155/2012/702839 |
0.541 |
|
| 2012 |
Haseley A, Boone S, Wojton J, Yu L, Yoo JY, Yu J, Kurozumi K, Glorioso JC, Caligiuri MA, Kaur B. Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma. Cancer Research. 72: 1353-62. PMID 22282654 DOI: 10.1158/0008-5472.Can-11-2526 |
0.535 |
|
| 2012 |
Li Z, Huang H, Li Y, Jiang X, Chen P, Arnovitz S, Radmacher MD, Maharry K, Elkahloun A, Yang X, He C, He M, Zhang Z, Dohner K, Neilly MB, ... ... Caligiuri MA, et al. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood. 119: 2314-24. PMID 22251480 DOI: 10.1182/Blood-2011-10-386235 |
0.3 |
|
| 2012 |
Dubovsky JA, Beckwith KA, Woyach JA, Jaglowski SM, Hessler J, Chang BY, Larkin K, Stefanovski MR, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, ... ... Caligiuri MA, et al. Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells Blood. 120: 775-775. DOI: 10.1182/Blood.V120.21.775.775 |
0.446 |
|
| 2012 |
Alachkar H, Maharry K, Santhanam R, Neviani P, Volinia S, Kohlschmidt J, Metzeler KH, Dorrance AM, Schwind S, Becker H, Mendler JH, Eisfeld A, Whitman S, Mrózek K, Garzon R, ... ... Caligiuri MA, et al. SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML) Blood. 120: 773-773. DOI: 10.1182/Blood.V120.21.773.773 |
0.699 |
|
| 2012 |
Benson DM, Cohen AD, Munshi NC, Jagannath S, Spitzer G, Hofmeister CC, Zerbib R, Andre P, Efebera YA, Oxier S, Caligiuri MA. A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results Blood. 120: 4058-4058. DOI: 10.1182/Blood.V120.21.4058.4058 |
0.381 |
|
| 2012 |
Yan X, Zhang Y, Sashida G, Chen A, Zhao X, Whitman S, Wang Q, Caligiuri MA, Xiao Z, Huang G. Modeling MLL-PTD Related Myelodysplastic Syndromes in Mouse. Blood. 120: 2811-2811. DOI: 10.1182/Blood.V120.21.2811.2811 |
0.354 |
|
| 2012 |
Briercheck EL, Trotta R, Cole JP, Cole TD, Hartlage AS, Martin CK, Leone G, Caligiuri MA. Human Natural Killer (NK) Cells: Differential Expression of Phosphatase and Tensin Homologue Deleted On Chromosome Ten (PTEN) During NK Cell Development Regulates Its Cytolytic Activity Against Leukemic Target Cells Blood. 120: 254-254. DOI: 10.1182/Blood.V120.21.254.254 |
0.83 |
|
| 2012 |
Yu J, He S, Wu L, Mao H, Vasu S, Jaglowski SM, Peng Y, Alvarez-Breckenridge C, Yuan S, Wei M, Zhang J, Hughes TL, Ghoshal K, Devine SM, Caligiuri MA. Micrornas Promote Activation and Maturation of Natural Killer Cells Through Toll-Like Receptor Signaling. Blood. 120: 2160-2160. DOI: 10.1182/Blood.V120.21.2160.2160 |
0.424 |
|
| 2012 |
Schwind S, Blum W, Liu S, Tarighat SS, Geyer S, Klisovic R, Eisfeld A, Walker A, Whitman S, Ramasamy S, Wu Y, Jacob S, Caligiuri M, Grever M, Perrotti D, et al. Abstract CT-06: The combination of bortezomib (BOR) and decitabine (DEC): A phase I trial in patients (pts) with acute myeloid leukemia (AML) targeting FLT3 expression Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Ct-06 |
0.386 |
|
| 2012 |
Mims AS, Walker AR, Hoellerbauer P, Huang X, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen C, Blum W, Garzon R, Schwind S, Marcucci G. Abstract 119: AR42, a histone deacetylase inhibitor (HDACI), increases microRNA (miR)-29b and sensitizes cells to decitabine (DAC) treatment: A novel epigenetic-targeting approach in acute myeloid leukemia (AML) Cancer Research. 72: 119-119. DOI: 10.1158/1538-7445.Am2012-119 |
0.369 |
|
| 2011 |
Vasu S, Caligiuri MA. Targeted immunotherapy for acute myeloid leukemia. Best Practice & Research. Clinical Haematology. 24: 533-40. PMID 22127317 DOI: 10.1016/J.Beha.2011.09.001 |
0.446 |
|
| 2011 |
Benson DM, Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S, Hofmeister CC, Efebera Y, Andre P, Romagne F, Bléry M, Bonnafous C, Zhang J, Clever D, Caligiuri MA, et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 118: 6387-91. PMID 22031859 DOI: 10.1182/Blood-2011-06-360255 |
0.455 |
|
| 2011 |
Schwind S, Marcucci G, Kohlschmidt J, Radmacher MD, Mrózek K, Maharry K, Becker H, Metzeler KH, Whitman SP, Wu YZ, Powell BL, Baer MR, Kolitz JE, Carroll AJ, Larson RA, ... Caligiuri MA, et al. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood. 118: 4188-98. PMID 21828125 DOI: 10.1182/Blood-2011-06-357764 |
0.304 |
|
| 2011 |
Yu J, Mitsui T, Wei M, Mao H, Butchar JP, Shah MV, Zhang J, Mishra A, Alvarez-Breckenridge C, Liu X, Liu S, Yokohama A, Trotta R, Marcucci G, Benson DM, ... ... Caligiuri MA, et al. NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. The Journal of Clinical Investigation. 121: 1456-70. PMID 21364281 DOI: 10.1172/Jci43242 |
0.47 |
|
| 2011 |
Kannan Y, Yu J, Raices RM, Seshadri S, Wei M, Caligiuri MA, Wewers MD. IκBζ augments IL-12- and IL-18-mediated IFN-γ production in human NK cells. Blood. 117: 2855-63. PMID 21224476 DOI: 10.1182/Blood-2010-07-294702 |
0.473 |
|
| 2011 |
Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science (New York, N.Y.). 331: 44-9. PMID 21212348 DOI: 10.1126/Science.1198687 |
0.432 |
|
| 2011 |
Trotta R, Ciarlariello D, Dal Col J, Mao H, Chen L, Briercheck E, Yu J, Zhang J, Perrotti D, Caligiuri MA. The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells. Blood. 117: 2378-84. PMID 21156847 DOI: 10.1182/Blood-2010-05-285130 |
0.817 |
|
| 2011 |
Mendler JH, Maharry K, Radmacher MD, Mrózek K, Kohlschmidt J, Nicolet D, Becker H, Metzeler KH, Schwind S, Whitman SP, Blum W, Powell BL, Kolitz JE, Carter TH, Wetzler M, ... ... Caligiuri MA, et al. Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures, Blood. 118: 3454-3454. DOI: 10.1182/Blood.V118.21.3454.3454 |
0.35 |
|
| 2011 |
Zhang Y, Yan X, Sashida G, Zhao X, Rao Y, Goyama S, Whitman SP, Zorko N, Bernot KM, Witte D, Wang Q, Tenen DG, Xiao Z, Marcucci G, Mulloy JC, ... Caligiuri MA, et al. MLL-PTD Causes Hypomorph Condition of CBF Complex (RUNX1/CBFβ) and Predisposes the Abnormal Hematopoietic Stem and Progenitor Cells (HSPCs) to Clonal Expansion Blood. 118: 2801-2801. DOI: 10.1182/Blood.V118.21.2801.2801 |
0.359 |
|
| 2011 |
Li Z, Huang H, Li Y, Jiang X, Chen P, Arnovitz S, Radmacher MD, Maharry K, Elkahloun A, Yang X, He C, Price CO, Dohner K, Zhang Z, Shen C, ... ... Caligiuri MA, et al. Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia Blood. 118: 236-236. DOI: 10.1182/Blood.V118.21.236.236 |
0.303 |
|
| 2011 |
Neviani P, Harb J, Oaks J, Walker C, Santhanam R, Paisie C, Eiring A, Zhang B, Perazzona B, Ma Y, Mao C, Marcucci G, Holyoake T, Volinia S, Cortes J, ... Caligiuri M, et al. Abstract LB-109: BCR-ABL1 kinase activity but not its expression is dispensable for Ph+ quiescent stem cell survival which depends on the PP2A-controlled Jak2 activation and is sensitive to FTY720 treatment Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-109 |
0.337 |
|
| 2011 |
Mishra A, Sams GH, Johns J, Curphey DP, Sullivan LA, Falkenberg LG, Gibson H, Liu S, Jaroncyk L, Carson W, Kulp SK, Chen C, Wong HK, Perle KL, Porcu P, ... ... Caligiuri MA, et al. Abstract 2858: A novel mouse model for cutaneous T-cell lymphoma reveals a role for IL-15 and activity of a new oral HDAC inhibitor Cancer Research. 71: 2858-2858. DOI: 10.1158/1538-7445.Am2011-2858 |
0.454 |
|
| 2010 |
Smith MA, Maurin M, Cho HI, Becknell B, Freud AG, Yu J, Wei S, Djeu J, Celis E, Caligiuri MA, Wright KL. PRDM1/Blimp-1 controls effector cytokine production in human NK cells. Journal of Immunology (Baltimore, Md. : 1950). 185: 6058-67. PMID 20944005 DOI: 10.4049/Jimmunol.1001682 |
0.674 |
|
| 2010 |
Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Becker H, Whitman SP, Wu YZ, Metzeler KH, Powell BL, Kolitz JE, Carter TH, Moore JO, ... ... Caligiuri MA, et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 116: 5660-9. PMID 20841507 DOI: 10.1182/Blood-2010-06-290536 |
0.327 |
|
| 2010 |
Male V, Hughes T, McClory S, Colucci F, Caligiuri MA, Moffett A. Immature NK cells, capable of producing IL-22, are present in human uterine mucosa. Journal of Immunology (Baltimore, Md. : 1950). 185: 3913-8. PMID 20802153 DOI: 10.4049/Jimmunol.1001637 |
0.813 |
|
| 2010 |
Whitman SP, Maharry K, Radmacher MD, Becker H, Mrózek K, Margeson D, Holland KB, Wu YZ, Schwind S, Metzeler KH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, ... ... Caligiuri MA, et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 116: 3622-6. PMID 20656931 DOI: 10.1182/Blood-2010-05-283648 |
0.326 |
|
| 2010 |
Hughes T, Becknell B, Freud AG, McClory S, Briercheck E, Yu J, Mao C, Giovenzana C, Nuovo G, Wei L, Zhang X, Gavrilin MA, Wewers MD, Caligiuri MA. Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. Immunity. 32: 803-14. PMID 20620944 DOI: 10.1016/J.Immuni.2010.06.007 |
0.816 |
|
| 2010 |
Benson DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, ... ... Caligiuri MA, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 116: 2286-94. PMID 20460501 DOI: 10.1182/Blood-2010-02-271874 |
0.338 |
|
| 2010 |
Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Paschka P, Holland KB, Schwind S, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, ... ... Caligiuri MA, et al. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 116: 788-92. PMID 20442368 DOI: 10.1182/Blood-2010-01-262543 |
0.346 |
|
| 2010 |
Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, ... ... Caligiuri MA, et al. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 17: 333-47. PMID 20385359 DOI: 10.1016/J.Ccr.2010.03.008 |
0.3 |
|
| 2010 |
Guimond M, Freud AG, Mao HC, Yu J, Blaser BW, Leong JW, Vandeusen JB, Dorrance A, Zhang J, Mackall CL, Caligiuri MA. In vivo role of Flt3 ligand and dendritic cells in NK cell homeostasis. Journal of Immunology (Baltimore, Md. : 1950). 184: 2769-75. PMID 20142363 DOI: 10.4049/Jimmunol.0900685 |
0.835 |
|
| 2010 |
Gowda A, Ramanunni A, Cheney C, Rozewski D, Kindsvogel W, Lehman A, Jarjoura D, Caligiuri M, Byrd JC, Muthusamy N. Differential effects of IL-2 and IL-21 on expansion of the CD4+ CD25+ Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia. Mabs. 2: 35-41. PMID 20081380 DOI: 10.4161/Mabs.2.1.10561 |
0.376 |
|
| 2010 |
Freud AG, Caligiuri MA. Purification of human NK cell developmental intermediates from lymph nodes and tonsils. Methods in Molecular Biology (Clifton, N.J.). 612: 1-14. PMID 20033630 DOI: 10.1007/978-1-60761-362-6_1 |
0.685 |
|
| 2010 |
Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu YZ, Schwind S, Paschka P, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, ... ... Caligiuri MA, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 596-604. PMID 20026798 DOI: 10.1200/Jco.2009.25.1496 |
0.32 |
|
| 2010 |
Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM, Roda JM, Cheney C, Mo X, Lehman A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, ... Caligiuri MA, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood. 115: 1204-13. PMID 19965644 DOI: 10.1182/Blood-2009-06-229039 |
0.42 |
|
| 2010 |
Yu J, Mao HC, Wei M, Hughes T, Zhang J, Park IK, Liu S, McClory S, Marcucci G, Trotta R, Caligiuri MA. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood. 115: 274-81. PMID 19897577 DOI: 10.1182/Blood-2009-04-215491 |
0.793 |
|
| 2010 |
Yokohama A, Mishra A, Mitsui T, Becknell B, Johns J, Curphey D, Blaser BW, Vandeusen JB, Mao H, Yu J, Caligiuri MA. A novel mouse model for the aggressive variant of NK cell and T cell large granular lymphocyte leukemia. Leukemia Research. 34: 203-9. PMID 19660811 DOI: 10.1016/J.Leukres.2009.06.031 |
0.731 |
|
| 2010 |
Benson DM, Padmanabhan S, Hofmeister CC, Bakan CE, Abonour R, Suvannasankha A, Efebera YA, Squiban PJ, Caligiuri MA, Farag S. A phase I study of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma. Journal of Clinical Oncology. 28: 8139-8139. DOI: 10.1200/Jco.2010.28.15_Suppl.8139 |
0.36 |
|
| 2010 |
Mishra A, Liu S, Sams GH, Curphey DP, Santhanam R, Rush LJ, Schaefer D, Falkenberg LG, Sullivan L, Jaroncyk L, Zou X, Fisk H, Labanowska J, Caserta E, Wu L, ... ... Caligiuri MA, et al. Interleukin-15 Is a Proto-Oncogene In Acute Large Granular Lymphocyte Leukemia Blood. 116: 704-704. DOI: 10.1182/Blood.V116.21.704.704 |
0.714 |
|
| 2010 |
Neviani P, Harb JG, Oaks JJ, Walker C, Santhanam R, Paisie C, Eiring A, Zhang B, Perazzona B, Ma Y, Mao C, Marcucci G, Holyoake TL, Volinia S, Cortes JE, ... Caligiuri MA, et al. BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment Blood. 116: 515-515. DOI: 10.1182/Blood.V116.21.515.515 |
0.398 |
|
| 2010 |
Park I, Mishra A, Chandler JC, Caligiuri MA. Effective Targeting of Acute Myeloid Leukemia (AML) Harboring the FLT3 ITD Mutation through the Axl/Gas6 Pathway Blood. 116: 500-500. DOI: 10.1182/Blood.V116.21.500.500 |
0.308 |
|
| 2010 |
Benson DM, Bakan CE, Padmanaban S, Abonour R, Suvannasankha A, Jagannath S, Chari A, Clever D, Kalu C, Collins S, Alghothani Y, Hofmeister CC, Efebera Y, Blanchet S, Caligiuri MA, et al. IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interm Phase 1 Trial Results and Correlative Biologic and Safety Data Blood. 116: 1966-1966. DOI: 10.1182/Blood.V116.21.1966.1966 |
0.372 |
|
| 2010 |
Zorko N, Whitman SP, Bernot K, Ngangana MT, Siebenaler R, Liu S, Wu Y, Kalu C, Zhang X, Jarjoura D, Xie Z, Chan KK, Dorrance AM, Lee BH, Briesewitz R, ... ... Caligiuri MA, et al. The Mll PTD and Flt3 ITD Double Knock-In Mouse Develops Acute Leukemia and Recapitulates Phenotypic, Molecular and Epigenetic Characteristics of the Counterpart Human Acute Myeloid Leukemia Blood. 116: 150-150. DOI: 10.1182/Blood.V116.21.150.150 |
0.38 |
|
| 2010 |
Schwind S, Marcucci G, Holland KB, Mrózek K, Michael RD, Maharry K, Becker H, Whitman SP, Wu Y, Carter TH, Powell BL, Caligiuri MA, Baer MR, Larson RA, Bloomfield CD. Abstract 2717: Higher MN1 expression is an unfavorable prognosticator in older patients (Pts) with cytogenetically normal acute myeloid leukemia (CN-AML): A CALGB study Cancer Research. 70: 2717-2717. DOI: 10.1158/1538-7445.Am10-2717 |
0.305 |
|
| 2010 |
Eiring AM, Harb J, Neviani P, Oaks JJ, Liu S, Spizzo R, Schwind S, Santhanam R, Hickey C, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, ... ... Caligiuri MA, et al. Abstract 1950: Suppression of RISC-independent decoy and RISC-mediated RNA-pairing activities of microRNA-328 is required for maturation-arrest and enhanced survival of blast crisis CML progenitors Cancer Research. 70: 1950-1950. DOI: 10.1158/1538-7445.Am10-1950 |
0.301 |
|
| 2010 |
Alvarez-Breckenridge CA, Yu J, Pradarelli J, Liu T, Kaur B, Caligiuri M, Chiocca EA. Abstract 1514: Oncolytic viral therapy for glioblastoma induces robust natural killer cell activation Cancer Research. 70: 1514-1514. DOI: 10.1158/1538-7445.Am10-1514 |
0.607 |
|
| 2009 |
Benson DM, Romagne F, Squiban P, Wagtmann N, Farag S, Mita A, Hofmeister C, Smith M, Bakan C, Caligiuri M. Novel monoclonal antibody that enhances natural killer (NK) cell cytotoxicity against multiple myeloma (MM): Preclinical data and interim phase I clinical trial results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3032. PMID 27962080 DOI: 10.1200/Jco.2009.27.15_Suppl.3032 |
0.412 |
|
| 2009 |
Yu J, Wei M, Mao H, Zhang J, Hughes T, Mitsui T, Park IK, Hwang C, Liu S, Marcucci G, Trotta R, Benson DM, Caligiuri MA. CD94 defines phenotypically and functionally distinct mouse NK cell subsets. Journal of Immunology (Baltimore, Md. : 1950). 183: 4968-74. PMID 19801519 DOI: 10.4049/Jimmunol.0900907 |
0.42 |
|
| 2009 |
Romagné F, André P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM, Blaser BW, Della Chiesa M, Moretta A, Vivier E, Caligiuri MA, Velardi A, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 114: 2667-77. PMID 19553639 DOI: 10.1182/Blood-2009-02-206532 |
0.436 |
|
| 2009 |
Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P, Whitman SP, Mrózek K, Baldus CD, Vij R, Powell BL, Carroll AJ, Kolitz JE, Caligiuri MA, Larson RA, et al. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3198-204. PMID 19451432 DOI: 10.1200/Jco.2008.20.6110 |
0.332 |
|
| 2009 |
Yu J, Ershler M, Yu L, Wei M, Hackanson B, Yokohama A, Mitsui T, Liu C, Mao H, Liu S, Liu Z, Trotta R, Liu CG, Liu X, Huang K, ... ... Caligiuri MA, et al. TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia. Blood. 113: 5558-67. PMID 19329776 DOI: 10.1182/Blood-2009-02-205732 |
0.441 |
|
| 2009 |
Hughes T, Becknell B, McClory S, Briercheck E, Freud AG, Zhang X, Mao H, Nuovo G, Yu J, Caligiuri MA. Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22. Blood. 113: 4008-10. PMID 19244159 DOI: 10.1182/Blood-2008-12-192443 |
0.828 |
|
| 2009 |
Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen CS, Johnson AJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. British Journal of Haematology. 144: 848-55. PMID 19183192 DOI: 10.1111/J.1365-2141.2008.07548.X |
0.438 |
|
| 2009 |
Benson DM, Yu J, Becknell B, Wei M, Freud AG, Ferketich AK, Trotta R, Perrotti D, Briesewitz R, Caligiuri MA. Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells. Blood. 113: 2706-14. PMID 19060242 DOI: 10.1182/Blood-2008-05-159285 |
0.734 |
|
| 2009 |
Mani A, Roda J, Young D, Caligiuri MA, Fleming GF, Kaufman P, Brufsky A, Ottman S, Carson WE, Shapiro CL. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Research and Treatment. 117: 83-9. PMID 19051009 DOI: 10.1007/S10549-008-0251-7 |
0.467 |
|
| 2009 |
Park IK, Giovenzana C, Hughes TL, Yu J, Trotta R, Caligiuri MA. The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development. Blood. 113: 2470-7. PMID 18840707 DOI: 10.1182/Blood-2008-05-157073 |
0.483 |
|
| 2009 |
Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu Y, Hickey C, Yu J, Mishra A, Becker H, Li C, Briesewitz R, Baiocchi RA, Chan KK, Caligiuri MA, et al. Evidence of MicroRNA-29b and Sp1/NFκB-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications. Blood. 114: 938-938. DOI: 10.1182/Blood.V114.22.938.938 |
0.412 |
|
| 2009 |
Benson D, Bakan CE, Alghothani L, Hofmeister CC, Efebera YA, Smith MK, Greenfield CN, Andre P, Squiban P, Romagne F, Caligiuri MA, Devine SM. Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma. Blood. 114: 4641-4641. DOI: 10.1182/Blood.V114.22.4641.4641 |
0.487 |
|
| 2009 |
Benson D, Bakan CE, Zhang S, Alghothani L, Liang J, Hofmeister C, Srivastava S, Smith MK, Greenfield CN, Andre P, Squiban P, Romagne F, Caligiuri MA, Farag S. IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect. Blood. 114: 3870-3870. DOI: 10.1182/Blood.V114.22.3870.3870 |
0.489 |
|
| 2009 |
Awan F, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson D, Cheney C, Mo X, Lehman A, Jones JA, Flynn JM, Jarjoura D, Baiocchi RA, Desjarlais J, Tridandapani S, ... Caligiuri MA, et al. CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody. Blood. 114: 3725-3725. DOI: 10.1182/Blood.V114.22.3725.3725 |
0.425 |
|
| 2009 |
Oaks J, Neviani P, Mukhopadhyay A, Santhanam R, Ma Y, Mao C, Marcucci G, Chen C, Cortes J, Caligiuri MA, Hokland P, Huettner C, Koschmieder S, Cancelas J, Briesewitz R, et al. FTY720 but Not Its Immunosuppressive Phosphorylated Form FTY720-P Exerts Anti-Leukemic Activity towards Ph(+) and Ph(−) Myeloproliferative Disorders through Reactivation of the PP2A Tumor Suppressor. Blood. 114: 3259-3259. DOI: 10.1182/Blood.V114.22.3259.3259 |
0.362 |
|
| 2009 |
Benson D, Hofmeister CC, Padmanabhan S, Abonour R, Suvannasankha A, Mita A, Squiban P, Smith MK, Bakan CE, Marzetto M, Andre P, Tollier J, Caligiuri MA, Farag S. Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results. Blood. 114: 2880-2880. DOI: 10.1182/Blood.V114.22.2880.2880 |
0.378 |
|
| 2009 |
Schwind S, Marcucci G, Maharry K, Mrózek K, Radmacher MD, Holland KB, Becker H, Whitman SP, Wu Y, Baer MR, Powell BL, Carroll AJ, Caligiuri MA, Larson RA, Bloomfield CD. Aberrant Gene Expression of BAALC and ERG in Older [≥60 Years (y)] De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study. Blood. 114: 214-214. DOI: 10.1182/Blood.V114.22.214.214 |
0.329 |
|
| 2009 |
Yip BH, Caligiuri MA, So CWE. Amplification of Histone Methyltransferase, Mixed-Lineage Leukemia (MLL), Perturbs Normal Hematopoiesis and Induces Hematological Disorder. Blood. 114: 1965-1965. DOI: 10.1182/Blood.V114.22.1965.1965 |
0.402 |
|
| 2008 |
Woyach JA, Lucas MS, Heerema NA, Moran ME, Lucas DM, Young D, Caligiuri MA, Lin TS, Byrd JC. Combination therapy with etanercept and rituximab in relapsed CLL/SLL. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 7065. PMID 27949630 DOI: 10.1200/Jco.2008.26.15_Suppl.7065 |
0.323 |
|
| 2008 |
Richards J, McNally B, Fang X, Caligiuri MA, Zheng P, Liu Y. Tumor growth decreases NK and B cells as well as common lymphoid progenitor. Plos One. 3: e3180. PMID 18784839 DOI: 10.1371/Journal.Pone.0003180 |
0.363 |
|
| 2008 |
Becknell B, Caligiuri MA. Natural killer cells in innate immunity and cancer. Journal of Immunotherapy (Hagerstown, Md. : 1997). 31: 685-92. PMID 18779751 DOI: 10.1097/Cji.0B013E318182De23 |
0.333 |
|
| 2008 |
Trotta R, Dal Col J, Yu J, Ciarlariello D, Thomas B, Zhang X, Allard J, Wei M, Mao H, Byrd JC, Perrotti D, Caligiuri MA. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. Journal of Immunology (Baltimore, Md. : 1950). 181: 3784-92. PMID 18768831 DOI: 10.4049/Jimmunol.181.6.3784 |
0.455 |
|
| 2008 |
Caligiuri MA. Human natural killer cells. Blood. 112: 461-9. PMID 18650461 DOI: 10.1182/Blood-2007-09-077438 |
0.458 |
|
| 2008 |
Dorrance AM, Liu S, Chong A, Pulley B, Nemer D, Guimond M, Yuan W, Chang D, Whitman SP, Marcucci G, Caligiuri MA. The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele. Blood. 112: 2508-11. PMID 18617636 DOI: 10.1182/Blood-2008-01-134338 |
0.686 |
|
| 2008 |
Whitman SP, Hackanson B, Liyanarachchi S, Liu S, Rush LJ, Maharry K, Margeson D, Davuluri R, Wen J, Witte T, Yu L, Liu C, Bloomfield CD, Marcucci G, Plass C, ... Caligiuri MA, et al. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood. 112: 2013-6. PMID 18566324 DOI: 10.1182/Blood-2008-01-128595 |
0.689 |
|
| 2008 |
Marcucci G, Radmacher MD, Maharry K, Mrózek K, Ruppert AS, Paschka P, Vukosavljevic T, Whitman SP, Baldus CD, Langer C, Liu CG, Carroll AJ, Powell BL, Garzon R, Croce CM, ... ... Caligiuri MA, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. The New England Journal of Medicine. 358: 1919-28. PMID 18450603 DOI: 10.1056/Nejmoa074256 |
0.309 |
|
| 2008 |
Lapalombella R, Zhao X, Triantafillou G, Yu B, Jin Y, Lozanski G, Cheney C, Heerema N, Jarjoura D, Lehman A, Lee LJ, Marcucci G, Lee RJ, Caligiuri MA, Muthusamy N, et al. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 569-78. PMID 18223233 DOI: 10.1158/1078-0432.Ccr-07-1006 |
0.363 |
|
| 2008 |
Gowda A, Roda J, Hussain SR, Ramanunni A, Joshi T, Schmidt S, Zhang X, Lehman A, Jarjoura D, Carson WE, Kindsvogel W, Cheney C, Caligiuri MA, Tridandapani S, Muthusamy N, et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood. 111: 4723-30. PMID 18182577 DOI: 10.1182/Blood-2007-07-099531 |
0.462 |
|
| 2008 |
Kondadasula SV, Roda JM, Parihar R, Yu J, Lehman A, Caligiuri MA, Tridandapani S, Burry RW, Carson WE. Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma. Blood. 111: 4173-83. PMID 18174382 DOI: 10.1182/Blood-2007-01-068908 |
0.448 |
|
| 2008 |
Swanson KD, Winter JM, Reis M, Bentires-Alj M, Greulich H, Grewal R, Hruban RH, Yeo CJ, Yassin Y, Iartchouk O, Montgomery K, Whitman SP, Caligiuri MA, Loh ML, Gilliland DG, et al. SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. Genes, Chromosomes & Cancer. 47: 253-9. PMID 18064648 DOI: 10.1002/Gcc.20527 |
0.309 |
|
| 2008 |
Whitman SP, Ruppert AS, Radmacher MD, Mrózek K, Paschka P, Langer C, Baldus CD, Wen J, Racke F, Powell BL, Kolitz JE, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 111: 1552-9. PMID 17940205 DOI: 10.1182/Blood-2007-08-107946 |
0.331 |
|
| 2008 |
Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M, Willis W, Gambacorti-Passerini C, Volinia S, Marcucci G, Caligiuri MA, Leone GW, Perrotti D. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. Blood. 111: 816-28. PMID 17925491 DOI: 10.1182/Blood-2007-05-090472 |
0.345 |
|
| 2008 |
Hughes TL, Becknell MB, Freud A, Schmidt SE, Yu J, Mao C, Gavrilin M, Wewers M, Caligiuri MA. The Stage-Specific Effect of Interleukin-1 Beta (IL-1β) during Human Natural Killer Cell Development Blood. 112: 3746-3746. DOI: 10.1182/blood.v112.11.3746.3746 |
0.666 |
|
| 2008 |
Neviani P, Santhanam R, Ma Y, Marcucci G, Byrd JC, Chen C, Cortes J, Caligiuri MA, Huettner C, Bhatia R, Roy D, Perrotti D. Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34+/CD38− Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL– independent Signals Blood. 112: 189-189. DOI: 10.1182/Blood.V112.11.189.189 |
0.417 |
|
| 2008 |
Mitsui T, Yu J, Yokohama A, Hughes TL, Shah MV, Loughran TP, Caligiuri MA. Characterization of An NKp46+ NKT Subset Which Is Susceptible to Malignant Transformation in Vivo. Blood. 112: 1546-1546. DOI: 10.1182/Blood.V112.11.1546.1546 |
0.482 |
|
| 2007 |
Opavsky R, Tsai SY, Guimond M, Arora A, Opavska J, Becknell B, Kaufmann M, Walton NA, Stephens JA, Fernandez SA, Muthusamy N, Felsher DW, Porcu P, Caligiuri MA, Leone G. Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis. Proceedings of the National Academy of Sciences of the United States of America. 104: 15400-5. PMID 17881568 DOI: 10.1073/Pnas.0706307104 |
0.351 |
|
| 2007 |
Trotta R, Ciarlariello D, Dal Col J, Allard J, Neviani P, Santhanam R, Mao H, Becknell B, Yu J, Ferketich AK, Thomas B, Modi A, Blaser BW, Perrotti D, Caligiuri MA. The PP2A inhibitor SET regulates natural killer cell IFN-gamma production. The Journal of Experimental Medicine. 204: 2397-405. PMID 17875674 DOI: 10.1084/Jem.20070419 |
0.465 |
|
| 2007 |
Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, ... ... Caligiuri MA, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. The Journal of Clinical Investigation. 117: 2408-21. PMID 17717597 DOI: 10.1172/Jci31095 |
0.371 |
|
| 2007 |
Yu J, Wei M, Boyd Z, Lehmann EB, Trotta R, Mao H, Liu S, Becknell B, Jaung MS, Jarjoura D, Marcucci G, Wu LC, Caligiuri MA. Transcriptional control of human T-BET expression: the role of Sp1. European Journal of Immunology. 37: 2549-61. PMID 17705132 DOI: 10.1002/Eji.200737088 |
0.365 |
|
| 2007 |
French AR, Kim S, Fehniger TA, Pratt JR, Yang L, Song YJ, Caligiuri MA, Yokoyama WM. Chronic lymphocytosis of functionally immature natural killer cells. The Journal of Allergy and Clinical Immunology. 120: 924-31. PMID 17604094 DOI: 10.1016/J.Jaci.2007.05.022 |
0.442 |
|
| 2007 |
Wang L, Wang J, Blaser BW, Duchemin AM, Kusewitt DF, Liu T, Caligiuri MA, Briesewitz R. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood. 110: 2075-83. PMID 17537993 DOI: 10.1182/Blood-2007-02-071266 |
0.363 |
|
| 2007 |
Chang JS, Santhanam R, Trotta R, Neviani P, Eiring AM, Briercheck E, Ronchetti M, Roy DC, Calabretta B, Caligiuri MA, Perrotti D. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. Blood. 110: 994-1003. PMID 17475908 DOI: 10.1182/Blood-2007-03-078303 |
0.779 |
|
| 2007 |
Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Kussewitt D, Lee RJ, Caligiuri MA, Tridandapani S, Muthusamy N, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood. 110: 2569-77. PMID 17440052 DOI: 10.1182/Blood-2006-12-062927 |
0.434 |
|
| 2007 |
Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, Lucas DM, Byrd JC. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2144-50. PMID 17404098 DOI: 10.1158/1078-0432.Ccr-06-2294 |
0.344 |
|
| 2007 |
Whitman SP, Ruppert AS, Marcucci G, Mrózek K, Paschka P, Langer C, Baldus CD, Wen J, Vukosavljevic T, Powell BL, Carroll AJ, Kolitz JE, Larson RA, Caligiuri MA, Bloomfield CD. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood. 109: 5164-7. PMID 17341662 DOI: 10.1182/Blood-2007-01-069831 |
0.307 |
|
| 2007 |
Becknell B, Hughes TL, Freud AG, Blaser BW, Yu J, Trotta R, Mao HC, Caligiuri de Jesús ML, Alghothani M, Benson DM, Lehman A, Jarjoura D, Perrotti D, Bates MD, Caligiuri MA. Hlx homeobox transcription factor negatively regulates interferon-gamma production in monokine-activated natural killer cells. Blood. 109: 2481-7. PMID 17110450 DOI: 10.1182/Blood-2006-10-050096 |
0.688 |
|
| 2007 |
Mani A, Roda J, Caligiuri M, Fleming G, Kaufman P, Brufsky A, Carson W, Shapiro C. A phase II trial of trastuzumab and low dose interleukin-2 in patients with metastatic breast cancer who have previously failed trastuzumab Journal of Clinical Oncology. 25: 3028-3028. DOI: 10.1200/Jco.2007.25.18_Suppl.3028 |
0.368 |
|
| 2007 |
Wagtmann N, Andre P, Zahn S, Spee P, Anfossi N, Gauthier L, Blaser BW, Caligiuri MA, Capanni M, Ruggeri L, Velardi A, Romagne F. Anti-KIR (1-7F9): A Fully Human Monoclonal Antibody (mAb) That Blocks KIR2DL1, −2 and −3, Promoting Natural Killer (NK) Cell-Mediated Lysis of Tumor Cells In Vitro and In Vivo. Blood. 110: 582-582. DOI: 10.1182/Blood.V110.11.582.582 |
0.444 |
|
| 2007 |
Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Gambacorti-Passerini C, Volinia S, Marcucci G, Caligiuri MA, Leone GW, Perrotti D. Requirement of the E2F3 Transcription Factor for BCR/ABL Leukemogenesis. Blood. 110: 33-33. DOI: 10.1182/Blood.V110.11.33.33 |
0.404 |
|
| 2007 |
Guimond M, Freud AG, Mao HC, Blaser BW, Lagemann GG, Vandeusen JB, Dorrance A, Ferketich AK, Cavalcanti M, Mackall CL, Caligiuri MA. Mechanism by Which Exogenous Administration of Flt3 Ligand (FL) Expands Natural Killer Cells In Vivo. Blood. 110: 2310-2310. DOI: 10.1182/Blood.V110.11.2310.2310 |
0.844 |
|
| 2007 |
Park I, Giovenzana C, Hughes TL, Yu J, Trotta R, Caligiuri MA. The Axl/Gas6 Pathway Is Required for Human Natural Killer Cell Development. Blood. 110: 2305-2305. DOI: 10.1182/Blood.V110.11.2305.2305 |
0.509 |
|
| 2007 |
Kolitz JE, Hars V, DeAngelo DJ, Allen SL, Shea TC, Vij R, Hoke E, Bloomfield CD, Caligiuri MA, George SL, Larson RA. Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808. Blood. 110: 157-157. DOI: 10.1182/Blood.V110.11.157.157 |
0.331 |
|
| 2006 |
Khan KD, Emmanouilides C, Benson DM, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, ... Caligiuri MA, et al. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 7046-53. PMID 17145827 DOI: 10.1158/1078-0432.Ccr-06-1571 |
0.328 |
|
| 2006 |
Freud AG, Caligiuri MA. Human natural killer cell development. Immunological Reviews. 214: 56-72. PMID 17100876 DOI: 10.1111/J.1600-065X.2006.00451.X |
0.702 |
|
| 2006 |
Palomero T, McKenna K, O-Neil J, Galinsky I, Stone R, Suzukawa K, Stiakaki E, Kalmanti M, Fox EA, Caligiuri MA, Aster JC, Look AT, Ferrando AA. Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias. Leukemia. 20: 1963-6. PMID 17008890 DOI: 10.1038/Sj.Leu.2404409 |
0.35 |
|
| 2006 |
Dorrance AM, Liu S, Yuan W, Becknell B, Arnoczky KJ, Guimond M, Strout MP, Feng L, Nakamura T, Yu L, Rush LJ, Weinstein M, Leone G, Wu L, Ferketich A, ... ... Caligiuri MA, et al. Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. The Journal of Clinical Investigation. 116: 2707-16. PMID 16981007 DOI: 10.1172/Jci25546 |
0.79 |
|
| 2006 |
Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J, Kaur B, Louis DN, Weissleder R, Caligiuri MA, Chiocca EA. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proceedings of the National Academy of Sciences of the United States of America. 103: 12873-8. PMID 16908838 DOI: 10.1073/Pnas.0605496103 |
0.566 |
|
| 2006 |
Shah MH, Freud AG, Benson DM, Ferkitich AK, Dezube BJ, Bernstein ZP, Caligiuri MA. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3993-6. PMID 16818697 DOI: 10.1158/1078-0432.Ccr-06-0268 |
0.715 |
|
| 2006 |
Blaser BW, Schwind NR, Karol S, Chang D, Shin S, Roychowdhury S, Becknell B, Ferketich AK, Kusewitt DF, Blazar BR, Caligiuri MA. Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity. Blood. 108: 2463-9. PMID 16757683 DOI: 10.1182/Blood-2006-04-019059 |
0.684 |
|
| 2006 |
Pichiorri F, Trapasso F, Palumbo T, Aqeilan RI, Drusco A, Blaser BW, Iliopoulos D, Caligiuri MA, Huebner K, Croce CM. Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3494-501. PMID 16740775 DOI: 10.1158/1078-0432.Ccr-05-2581 |
0.304 |
|
| 2006 |
Yu J, Wei M, Becknell B, Trotta R, Liu S, Boyd Z, Jaung MS, Blaser BW, Sun J, Benson DM, Mao H, Yokohama A, Bhatt D, Shen L, Davuluri R, ... ... Caligiuri MA, et al. Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity. 24: 575-90. PMID 16713975 DOI: 10.1016/J.Immuni.2006.03.016 |
0.427 |
|
| 2006 |
Farag SS, Caligiuri MA. Immunologic approaches to acute leukemia in the elderly. Seminars in Hematology. 43: 118-25. PMID 16616045 DOI: 10.1053/J.Seminhematol.2006.01.006 |
0.455 |
|
| 2006 |
Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, Ferketich AK, Caligiuri MA. Evidence for discrete stages of human natural killer cell differentiation in vivo. The Journal of Experimental Medicine. 203: 1033-43. PMID 16606675 DOI: 10.1084/Jem.20052507 |
0.71 |
|
| 2006 |
Richards JO, Chang X, Blaser BW, Caligiuri MA, Zheng P, Liu Y. Tumor growth impedes natural-killer-cell maturation in the bone marrow Blood. 108: 246-252. PMID 16556890 DOI: 10.1182/Blood-2005-11-4535 |
0.485 |
|
| 2006 |
Ganesan LP, Joshi T, Fang H, Kutala VK, Roda J, Trotta R, Lehman A, Kuppusamy P, Byrd JC, Carson WE, Caligiuri MA, Tridandapani S. FcgammaR-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways. Blood. 108: 718-25. PMID 16543474 DOI: 10.1182/Blood-2005-09-3889 |
0.33 |
|
| 2006 |
Blaser BW, Caligiuri MA. Autologous immune strategies to reduce the risk of leukemic relapse: Consideration for IL-15 Best Practice and Research: Clinical Haematology. 19: 281-292. PMID 16516125 DOI: 10.1016/J.Beha.2005.11.004 |
0.413 |
|
| 2006 |
VanDeusen JB, Shah MH, Becknell B, Blaser BW, Ferketich AK, Nuovo GJ, Ahmer BM, Durbin J, Caligiuri MA. STAT-1-mediated repression of monocyte interleukin-10 gene expression in vivo. European Journal of Immunology. 36: 623-30. PMID 16482512 DOI: 10.1002/Eji.200535241 |
0.674 |
|
| 2006 |
Mikhalkevich N, Becknell B, Caligiuri MA, Bates MD, Harvey R, Zheng WP. Responsiveness of naive CD4 T cells to polarizing cytokine determines the ratio of Th1 and Th2 cell differentiation Journal of Immunology. 176: 1553-1560. PMID 16424184 DOI: 10.4049/Jimmunol.176.3.1553 |
0.458 |
|
| 2006 |
Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Reviews. 20: 123-37. PMID 16364519 DOI: 10.1016/J.Blre.2005.10.001 |
0.534 |
|
| 2006 |
Glaser R, Litsky ML, Padgett DA, Baiocchi RA, Yang EV, Chen M, Yeh PE, Green-Church KB, Caligiuri MA, Williams MV. EBV-encoded dUTPase induces immune dysregulation: Implications for the pathophysiology of EBV-associated disease. Virology. 346: 205-18. PMID 16321417 DOI: 10.1016/J.Virol.2005.10.034 |
0.415 |
|
| 2006 |
Notari M, Neviani P, Santhanam R, Blaser BW, Chang JS, Galietta A, Willis AE, Roy DC, Caligiuri MA, Marcucci G, Perrotti D. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood. 107: 2507-16. PMID 16293596 DOI: 10.1182/Blood-2005-09-3732 |
0.382 |
|
| 2006 |
Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Advances in Immunology. 86: 209-39. PMID 15705423 DOI: 10.1016/S0065-2776(04)86006-1 |
0.501 |
|
| 2006 |
Benson DM, Shah M, Freud A, Ferketich A, Dezube BJ, Bernstein ZP, Caligiuri MA. A phase I study of ultra low dose interleukin-2 (IL-2) and stem cell factor (SCF) in patients with cancer and or HIV infection Journal of Clinical Oncology. 24: 2503-2503. DOI: 10.1200/Jco.2006.24.18_Suppl.2503 |
0.697 |
|
| 2006 |
Trotta R, Col JD, Allard J, Neviani P, Santhanam R, Mao H, Becknell B, Yu J, Modi A, Blaser BW, Perrotti D, Caligiuri MA. In Vitro and In Vivo Evidence That the PP2A Inhibitor SET Regulates IFN-γ Production in Monokine-Stimulated Natural Killer Cells. Blood. 108: 928-928. DOI: 10.1182/Blood.V108.11.928.928 |
0.486 |
|
| 2006 |
Whitman SP, Wen J, Muto G, Hackanson B, Yu L, Liu C, Sanfilippo JL, Marcucci G, Rush LJ, Plass C, Caligiuri MA. The Tumor Suppressor Gene SLC5A8 Is Selectively Silenced in MLL Partial Tandem Duplication-Positive Acute Myeloid Leukemia with Normal Cytogenetics. Blood. 108: 9-9. DOI: 10.1182/Blood.V108.11.9.9 |
0.676 |
|
| 2006 |
Baer MR, George SL, Caligiuri MA, Sanford BL, O’Loughlin KL, Mrozek K, Kolitz JE, Powell BL, Moore JO, Stone RM, Bloomfield CD, Larson RA. Phase III Study of Immunotherapy with Recombinant Interleukin-2 (IL-2) Versus No Further Therapy in Acute Myeloid Leukemia (AML) Patients ≥ 60 Years in First Complete Remission (CALGB 9720). Blood. 108: 424-424. DOI: 10.1182/Blood.V108.11.424.424 |
0.35 |
|
| 2006 |
Santhanam R, Neviani P, Eiring A, Oaks J, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Marcucci G, Gambacorti C, Roy D, Caligiuri MA, Bloomfield CD, Chen C, et al. FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph1 ALL Patients. Blood. 108: 288-288. DOI: 10.1182/Blood.V108.11.288.288 |
0.426 |
|
| 2006 |
Chang J, Santhanam R, Briercheck E, Eiring A, Trotta R, Notari M, Roy D, Caligiuri MA, Perrotti D. Molecular and Pharmacologic Suppression of MAPK Activity Rescues Differentiation of BCR/ABL+ Myeloid Progenitors by Releasing C/EBPa from the Inhibitory Effect of hnRNP E2. Blood. 108: 2240-2240. DOI: 10.1182/Blood.V108.11.2240.2240 |
0.785 |
|
| 2006 |
Yu J, Yu L, Hackanson B, Wei M, Boyd Z, Yokohama A, Liu C, Trotta R, Mao HC, Becknell B, Jaung MS, Liu S, Byrd JC, Marcucci G, Plass C, ... Caligiuri MA, et al. In Vitro and In Vivo Evidence That TSC-22 Is a Putative Tumor Suppressor Gene in Primary Murine and Human Leukemia. Blood. 108: 2211-2211. DOI: 10.1182/Blood.V108.11.2211.2211 |
0.447 |
|
| 2006 |
Zhao XB, Trupti J, Lapalombella R, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Lee RJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC. NK Cells Contribute Significantly to the Innate Immune Effector Role of CD37-Specific SMIP in CLL and NHL. Blood. 108: 135-135. DOI: 10.1182/Blood.V108.11.135.135 |
0.425 |
|
| 2005 |
Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, Roy DC, Valtieri M, Bruner-Klisovic R, Caligiuri MA, Bloomfield CD, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 8: 355-68. PMID 16286244 DOI: 10.1016/J.Ccr.2005.10.015 |
0.381 |
|
| 2005 |
Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrózek K, Whitman SP, Kolitz JE, Edwards CG, Vardiman JW, Powell BL, Baer MR, Moore JO, Perrotti D, Caligiuri MA, Carroll AJ, et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 9234-42. PMID 16275934 DOI: 10.1200/Jco.2005.03.6137 |
0.34 |
|
| 2005 |
Roychowdhury S, Caligiuri MA. Cytokine therapy for cancer: antigen presentation. Cancer Treatment and Research. 123: 249-66. PMID 16211874 DOI: 10.1007/0-387-27545-2_11 |
0.596 |
|
| 2005 |
Parihar R, Trotta R, Roda JM, Ferketich AK, Tridandapani S, Caligiuri MA, Carson WE. Src homology 2-containing inositol 5'-phosphatase 1 negatively regulates IFN-gamma production by natural killer cells stimulated with antibody-coated tumor cells and interleukin-12. Cancer Research. 65: 9099-107. PMID 16204085 DOI: 10.1158/0008-5472.Can-04-4424 |
0.506 |
|
| 2005 |
Wang L, Baiocchi RA, Pal S, Mosialos G, Caligiuri M, Sif S. The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene. Molecular and Cellular Biology. 25: 7953-65. PMID 16135788 DOI: 10.1128/Mcb.25.18.7953-7965.2005 |
0.41 |
|
| 2005 |
Mone A, Puhalla S, Whitman S, Baiocchi RA, Cruz J, Vukosavljevic T, Banks A, Eisenbeis CF, Byrd JC, Caligiuri MA, Porcu P. Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia. Blood. 106: 3380-2. PMID 16076875 DOI: 10.1182/Blood-2005-01-0335 |
0.416 |
|
| 2005 |
Roychowdhury S, Blaser BW, Freud AG, Katz K, Bhatt D, Ferketich AK, Bergdall V, Kusewitt D, Baiocchi RA, Caligiuri MA. IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease. Blood. 106: 2433-5. PMID 15976176 DOI: 10.1182/Blood-2005-04-1597 |
0.782 |
|
| 2005 |
Dai G, Chan KK, Liu S, Hoyt D, Whitman S, Klisovic M, Shen T, Caligiuri MA, Byrd J, Grever M, Marcucci G. Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 2998-3008. PMID 15837754 DOI: 10.1158/1078-0432.Ccr-04-1505 |
0.306 |
|
| 2005 |
Freud AG, Becknell B, Roychowdhury S, Mao HC, Ferketich AK, Nuovo GJ, Hughes TL, Marburger TB, Sung J, Baiocchi RA, Guimond M, Caligiuri MA. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity. 22: 295-304. PMID 15780987 DOI: 10.1016/J.Immuni.2005.01.013 |
0.81 |
|
| 2005 |
Whitman SP, Liu S, Vukosavljevic T, Rush LJ, Yu L, Liu C, Klisovic MI, Maharry K, Guimond M, Strout MP, Becknell B, Dorrance A, Klisovic RB, Plass C, Bloomfield CD, ... ... Caligiuri MA, et al. The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood. 106: 345-52. PMID 15774615 DOI: 10.1182/Blood-2005-01-0204 |
0.791 |
|
| 2005 |
Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ, Raval A, Liu TH, Ding W, Mao C, Liu S, Smith LT, Lee S, Rassenti L, Marcucci G, ... ... Caligiuri MA, et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nature Genetics. 37: 265-74. PMID 15723065 DOI: 10.1038/Ng1521 |
0.31 |
|
| 2005 |
Trotta R, Parihar R, Yu J, Becknell B, Allard J, Wen J, Ding W, Mao H, Tridandapani S, Carson WE, Caligiuri MA. Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation. Blood. 105: 3011-8. PMID 15604218 DOI: 10.1182/Blood-2004-10-4072 |
0.46 |
|
| 2005 |
Dierksheide JE, Baiocchi RA, Ferketich AK, Roychowdhury S, Pelletier RP, Eisenbeis CF, Caligiuri MA, VanBuskirk AM. IFN-γ gene polymorphisms associate with development of EBV + lymphoproliferative disease in hu PBL-SCID mice Blood. 105: 1558-1565. PMID 15498860 DOI: 10.1182/Blood-2003-07-2476 |
0.637 |
|
| 2005 |
May KF, Roychowdhury S, Bhatt D, Kocak E, Bai XF, Liu JQ, Ferketich AK, Martin EW, Caligiuri MA, Zheng P, Liu Y. Anti-human CTLA-4 monoclonal antibody promotes T-cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies. Blood. 105: 1114-20. PMID 15486062 DOI: 10.1182/Blood-2004-07-2561 |
0.637 |
|
| 2005 |
Blaser BW, Roychowdhury S, Kim DJ, Schwind NR, Bhatt D, Yuan W, Kusewitt DF, Ferketich AK, Caligiuri MA, Guimond M. Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease. Blood. 105: 894-901. PMID 15374888 DOI: 10.1182/Blood-2004-05-1687 |
0.686 |
|
| 2005 |
Porcu P, Mone A, Puhalla S, Whitman S, Baiocchi R, Caligiuri M, Byrd J. Durable complete response (CR) and suppression of the human T-cell leukemia virus (HTLV-1) viral load (VL) with alemtuzumab in refractory adult T-cell leukemia (ATL) Journal of Clinical Oncology. 23: 6639-6639. DOI: 10.1200/Jco.2005.23.16_Suppl.6639 |
0.431 |
|
| 2005 |
Arnoczky KJ, Marburger TB, Vukosavljevic T, Caligiuri MA, Whitman SP. Aberrant Pre-mRNA Processing Due to Novel Splicing Mutations in the CBL Proto-Oncogene in Acute Myeloid Leukemia. Blood. 106: 4400-4400. DOI: 10.1182/Blood.V106.11.4400.4400 |
0.352 |
|
| 2005 |
Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Chang J, Liu S, Mao H, Oaks JJ, Roy DC, Valtieri M, Bruner-Klisovic R, Caligiuri MA, Bloomfield CD, Marcucci G, et al. ReSETting PP2A Tumor Suppressor Activity Overcomes BCR/ABL Leukemogenic Potential in Blast Crisis CML. Blood. 106: 1992-1992. DOI: 10.1182/Blood.V106.11.1992.1992 |
0.393 |
|
| 2004 |
Eisenbeis CF, Leonard J, Rosenblatt J, Khan KD, Porcu P, Milan S, Wilson SE, Hurst D, Caligiuri MA, Piro L. Conversion of antibody-resistant cancer patients to antibody-sensitive: Investigation of Fc receptor polymorphisms and response to IL-2 and rituximab treatment in rituximab-refractory NHL patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2534. PMID 28015238 DOI: 10.1200/Jco.2004.22.14_Suppl.2534 |
0.362 |
|
| 2004 |
Cooper MA, Caligiuri MA. Isolation and characterization of human natural killer cell subsets Current Protocols in Immunology / Edited by John E. Coligan ... [Et Al.]. PMID 18432933 DOI: 10.1002/0471142735.Im0734S60 |
0.693 |
|
| 2004 |
Becknell B, Trotta R, Yu J, Ding W, Mao HC, Hughes T, Marburger T, Caligiuri MA. Efficient infection of human natural killer cells with an EBV/retroviral hybrid vector. Journal of Immunological Methods. 296: 115-23. PMID 15680156 DOI: 10.1016/J.Jim.2004.11.012 |
0.441 |
|
| 2004 |
Caligiuri MA, Velardi A, Scheinberg DA, Borrello IM. Immunotherapeutic approaches for hematologic malignancies. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 337-53. PMID 15561691 DOI: 10.1182/Asheducation-2004.1.337 |
0.371 |
|
| 2004 |
Roychowdhury S, May KF, Tzou KS, Lin T, Bhatt D, Freud AG, Guimond M, Ferketich AK, Liu Y, Caligiuri MA. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Research. 64: 8062-7. PMID 15520217 DOI: 10.1158/0008-5472.Can-04-1860 |
0.785 |
|
| 2004 |
Yu L, Liu C, Bennett K, Wu YZ, Dai Z, Vandeusen J, Opavsky R, Raval A, Trikha P, Rodriguez B, Becknell B, Mao C, Lee S, Davuluri RV, Leone G, ... ... Caligiuri MA, et al. A NotI-EcoRV promoter library for studies of genetic and epigenetic alterations in mouse models of human malignancies. Genomics. 84: 647-60. PMID 15475242 DOI: 10.1016/J.Ygeno.2004.06.010 |
0.336 |
|
| 2004 |
Roychowdhury S, Baiocchi RA, Vourganti S, Bhatt D, Blaser BW, Freud AG, Chou J, Chen CS, Xiao JJ, Parthun M, Chan KK, Eisenbeis CF, Ferketich AK, Grever MR, Chen CS, ... Caligiuri MA, et al. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder. Journal of the National Cancer Institute. 96: 1447-57. PMID 15467034 DOI: 10.1093/Jnci/Djh271 |
0.739 |
|
| 2004 |
Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, Kelbick N, Stephens J, Byrd JC, Grever MR, Caligiuri MA, et al. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6101-10. PMID 15447996 DOI: 10.1158/1078-0432.Ccr-04-0525 |
0.695 |
|
| 2004 |
Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood. 104: 170-7. PMID 15016654 DOI: 10.1182/Blood-2003-12-4438 |
0.444 |
|
| 2004 |
Ferrando AA, Neuberg DS, Dodge RK, Paietta E, Larson RA, Wiernik PH, Rowe JM, Caligiuri MA, Bloomfield CD, Look AT. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet. 363: 535-6. PMID 14975618 DOI: 10.1016/S0140-6736(04)15542-6 |
0.393 |
|
| 2004 |
Perrotti D, Marcucci G, Caligiuri MA. Loss of C/EBP alpha and favorable prognosis of acute myeloid leukemias: a biological paradox. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 582-4. PMID 14726508 DOI: 10.1200/Jco.2004.12.965 |
0.346 |
|
| 2004 |
Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA. NK cell and DC interactions. Trends in Immunology. 25: 47-52. PMID 14698284 DOI: 10.1016/J.It.2003.10.012 |
0.641 |
|
| 2004 |
Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu Y, Raval A, Liu T, Ding W, Mao C, Liu S, Smith LT, Lee S, Rassenti L, Marcucci G, ... ... Caligiuri MA, et al. Global Assessment of Promoter Methylation in a Murine Model of Cancer Identifies ID4 as a Putative Novel Tumor Suppressor Gene in Human Leukemia. Blood. 104: 3488-3488. DOI: 10.1182/Blood.V104.11.3488.3488 |
0.412 |
|
| 2004 |
Lin TS, Heerema NA, Swenor J, Lucas MS, Moran ME, Cheney CM, Lucas DM, Young D, Caligiuri MA, Grever MR, Byrd JC. A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities. Blood. 104: 3469-3469. DOI: 10.1182/Blood.V104.11.3469.3469 |
0.314 |
|
| 2004 |
Freud AG, Becknell B, Roychowdhury S, Mao HC, Ferketich AK, Nuovo GJ, Hughes TL, Marburger TB, Sung J, Baiocchi RA, Guimond M, Caligiuri MA. A Novel Human CD34(+) Subset That Constitutively Expresses the High Affinity Interleukin-2 Receptor Traffics to Lymph Nodes and Differentiates into CD56Bright Natural Killer Cells. Blood. 104: 314-314. DOI: 10.1182/Blood.V104.11.314.314 |
0.816 |
|
| 2004 |
Becknell B, Trotta R, Yu J, Ding W, Mao HC, Hughes T, Marburger T, Caligiuri MA. Efficient and Reproducible Retroviral Infection of Primary Human Natural Killer Cells. Blood. 104: 1348-1348. DOI: 10.1182/Blood.V104.11.1348.1348 |
0.459 |
|
| 2004 |
Yu J, Becknell B, Liu S, Trotta R, Jaung MS, Hughes T, Marcucci G, Weinstein MB, Caligiuri MA. Elucidation of the Molecular Mechanisms by Which Inflammatory and Anti-Inflammatory Monokines Regulate Interferon (IFN)- γ Production. Blood. 104: 111-111. DOI: 10.1182/Blood.V104.11.111.111 |
0.451 |
|
| 2003 |
Ley TJ, Minx PJ, Walter MJ, Ries RE, Sun H, McLellan M, DiPersio JF, Link DC, Tomasson MH, Graubert TA, McLeod H, Khoury H, Watson M, Shannon W, Trinkaus K, ... ... Caligiuri MA, et al. A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. Proceedings of the National Academy of Sciences of the United States of America. 100: 14275-80. PMID 14614138 DOI: 10.1073/Pnas.2335924100 |
0.357 |
|
| 2003 |
Baldus CD, Tanner SM, Kusewitt DF, Liyanarachchi S, Choi C, Caligiuri MA, Bloomfield CD, de la Chapelle A. BAALC, a novel marker of human hematopoietic progenitor cells. Experimental Hematology. 31: 1051-6. PMID 14585369 DOI: 10.1016/J.Exphem.2003.08.004 |
0.349 |
|
| 2003 |
Becknell B, Shen T, Maghraby E, Taya S, Kaibuchi K, Caligiuri MA, Marcucci G. Characterization of leukemia-associated Rho guanine nucleotide exchange factor (LARG) expression during murine development. Cell and Tissue Research. 314: 361-6. PMID 14513355 DOI: 10.1007/S00441-003-0802-5 |
0.314 |
|
| 2003 |
Gao JX, Liu X, Wen J, Caligiuri MA, Stroynowski I, Zheng P, Liu Y. Two-signal requirement for activation and effector function of natural killer cell response to allogeneic tumor cells. Blood. 102: 4456-63. PMID 12933569 DOI: 10.1182/Blood-2003-07-2480 |
0.445 |
|
| 2003 |
Marcucci G, Caligiuri MA, Bloomfield CD. Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically? European Journal of Haematology. 71: 143-54. PMID 12930314 DOI: 10.1034/J.1600-0609.2003.00131.X |
0.317 |
|
| 2003 |
Farag SS, VanDeusen JB, Fehniger TA, Caligiuri MA. Biology and clinical impact of human natural killer cells. International Journal of Hematology. 78: 7-17. PMID 12894845 DOI: 10.1007/Bf02983234 |
0.749 |
|
| 2003 |
Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proceedings of the National Academy of Sciences of the United States of America. 100: 7830-5. PMID 12808148 DOI: 10.1073/Pnas.0932698100 |
0.394 |
|
| 2003 |
Colucci F, Caligiuri MA, Di Santo JP. What does it take to make a natural killer? Nature Reviews. Immunology. 3: 413-25. PMID 12766763 DOI: 10.1038/Nri1088 |
0.467 |
|
| 2003 |
Baldus CD, Tanner SM, Ruppert AS, Whitman SP, Archer KJ, Marcucci G, Caligiuri MA, Carroll AJ, Vardiman JW, Powell BL, Allen SL, Moore JO, Larson RA, Kolitz JE, de la Chapelle A, et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood. 102: 1613-8. PMID 12750167 DOI: 10.1182/Blood-2003-02-0359 |
0.326 |
|
| 2003 |
Tridandapani S, Wardrop R, Baran CP, Wang Y, Opalek JM, Caligiuri MA, Marsh CB. TGF-beta 1 suppresses [correction of supresses] myeloid Fc gamma receptor function by regulating the expression and function of the common gamma-subunit. Journal of Immunology (Baltimore, Md. : 1950). 170: 4572-7. PMID 12707335 DOI: 10.4049/Jimmunol.170.9.4572 |
0.31 |
|
| 2003 |
Farag SS, Fehniger TA, Becknell B, Blaser BW, Caligiuri MA. New directions in natural killer cell-based immunotherapy of human cancer. Expert Opinion On Biological Therapy. 3: 237-50. PMID 12662139 DOI: 10.1517/14712598.3.2.237 |
0.462 |
|
| 2003 |
Trotta R, Vignudelli T, Candini O, Intine RV, Pecorari L, Guerzoni C, Santilli G, Byrom MW, Goldoni S, Ford LP, Caligiuri MA, Maraia RJ, Perrotti D, Calabretta B. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell. 3: 145-60. PMID 12620409 DOI: 10.1016/S1535-6108(03)00020-5 |
0.35 |
|
| 2003 |
Roychowdhury S, Peng R, Baiocchi RA, Bhatt D, Vourganti S, Grecula J, Gupta N, Eisenbeis CF, Nuovo GJ, Yang W, Schmalbrock P, Ferketich A, Moeschberger M, Porcu P, Barth RF, ... Caligiuri MA, et al. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Research. 63: 965-71. PMID 12615710 |
0.622 |
|
| 2003 |
Becknell B, Caligiuri MA. Cancer T cell therapy expands. Nature Medicine. 9: 257-8. PMID 12612567 DOI: 10.1038/Nm0303-257 |
0.321 |
|
| 2003 |
Jilani I, Estey E, Manshuri T, Caligiuri M, Keating M, Giles F, Thomas D, Kantarjian HM, Albitar M. Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA Leukemia. 17: 114-119. PMID 12529667 DOI: 10.1038/Sj.Leu.2402743 |
0.303 |
|
| 2003 |
VanDeusen JB, Caligiuri MA. New developments in anti-tumor efficacy and malignant transformation of human natural killer cells. Current Opinion in Hematology. 10: 55-9. PMID 12483112 DOI: 10.1097/00062752-200301000-00009 |
0.721 |
|
| 2003 |
Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 101: 3052-7. PMID 12480696 DOI: 10.1182/Blood-2002-09-2876 |
0.698 |
|
| 2003 |
Farag SS, Fehniger T, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cells: biology and application in stem-cell transplantation. Cytotherapy. 4: 445-6. PMID 12473220 DOI: 10.1080/146532402320776134 |
0.345 |
|
| 2003 |
Marcucci G, Byrd JC, Dai G, Klisovic MI, Kourlas PJ, Young DC, Cataland SR, Fisher DB, Lucas D, Chan KK, Porcu P, Lin ZP, Farag SF, Frankel SR, Zwiebel JA, ... ... Caligiuri MA, et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood. 101: 425-32. PMID 12393493 DOI: 10.1182/Blood-2002-06-1899 |
0.309 |
|
| 2003 |
Durbin J, Doughty L, Nguyen K, Caligiuri M, Van Deusen J, Biron C. The role of STAT1 in viral sensitization to LPS Journal of Endotoxin Research. 9: 313-316. DOI: 10.1177/09680519030090050701 |
0.324 |
|
| 2003 |
Cooper MA, Caligiuri MA. Cytokines and cancer The Cytokine Handbook. 1213-1232. DOI: 10.1016/B978-012689663-3/50057-0 |
0.568 |
|
| 2002 |
Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, Aguila HL, Caligiuri MA. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood. 100: 3633-8. PMID 12393617 DOI: 10.1182/Blood-2001-12-0293 |
0.8 |
|
| 2002 |
Biber JL, Jabbour S, Parihar R, Dierksheide J, Hu Y, Baumann H, Bouchard P, Caligiuri MA, Carson W. Administration of two macrophage-derived interferon-gamma-inducing factors (IL-12 and IL-15) induces a lethal systemic inflammatory response in mice that is dependent on natural killer cells but does not require interferon-gamma. Cellular Immunology. 216: 31-42. PMID 12381348 DOI: 10.1016/S0008-8749(02)00501-4 |
0.425 |
|
| 2002 |
Nguyen KB, Salazar-Mather TP, Dalod MY, Van Deusen JB, Wei XQ, Liew FY, Caligiuri MA, Durbin JE, Biron CA. Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. Journal of Immunology (Baltimore, Md. : 1950). 169: 4279-87. PMID 12370359 DOI: 10.4049/Jimmunol.169.8.4279 |
0.472 |
|
| 2002 |
Porcu P, Eisenbeis CF, Pelletier RP, Davies EA, Baiocchi RA, Roychowdhury S, Vourganti S, Nuovo GJ, Marsh WL, Ferketich AK, Henry ML, Ferguson RM, Caligiuri MA. Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration. Blood. 100: 2341-8. PMID 12239141 DOI: 10.1182/Blood-2002-01-0210 |
0.65 |
|
| 2002 |
Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood. 100: 1935-47. PMID 12200350 DOI: 10.1182/Blood-2002-02-0350 |
0.421 |
|
| 2002 |
Cooper MA, Caligiuri MA. Immunologic manipulation in AML: From bench to bedside Leukemia. 16: 736-737. PMID 11960357 DOI: 10.1038/Sj.Leu.2402411 |
0.665 |
|
| 2002 |
Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine & Growth Factor Reviews. 13: 169-83. PMID 11900992 DOI: 10.1016/S1359-6101(01)00021-1 |
0.638 |
|
| 2002 |
Fehniger TA, Caligiuri MA. Ontogeny and expansion of human natural killer cells: clinical implications. International Reviews of Immunology. 20: 503-34. PMID 11878513 DOI: 10.3109/08830180109054417 |
0.498 |
|
| 2002 |
Rush LJ, Heinonen K, Mrózek K, Wolf BJ, Abdel-Rahman M, Szymanska J, Peltomäki P, Kapadia F, Bloomfield CD, Caligiuri MA, Plass C. Comprehensive cytogenetic and molecular genetic characterization of the TI-1 acute myeloid leukemia cell line reveals cross-contamination with K-562 cell line. Blood. 99: 1874-6. PMID 11871388 DOI: 10.1182/Blood.V99.5.1874 |
0.671 |
|
| 2002 |
Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K, Iervolino A, Condorelli F, Gambacorti-Passerini C, Caligiuri MA, Calabretta B. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nature Genetics. 30: 48-58. PMID 11753385 DOI: 10.1038/Ng791 |
0.369 |
|
| 2001 |
Comella K, Nakamura M, Melnik K, Chosy J, Zborowski M, Cooper MA, Fehniger TA, Caligiuri MA, Chalmers JJ. Effects of antibody concentration on the separation of human natural killer cells in a commercial immunomagnetic separation system. Cytometry. 45: 285-93. PMID 11746098 DOI: 10.1002/1097-0320(20011201)45:4<285::Aid-Cyto10018>3.0.Co;2-W |
0.595 |
|
| 2001 |
Tanner SM, Austin JL, Leone G, Rush LJ, Plass C, Heinonen K, Mrózek K, Sill H, Knuutila S, Kolitz JE, Archer KJ, Caligiuri MA, Bloomfield CD, de La Chapelle A. BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proceedings of the National Academy of Sciences of the United States of America. 98: 13901-6. PMID 11707601 DOI: 10.1073/Pnas.241525498 |
0.704 |
|
| 2001 |
Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends in Immunology. 22: 633-40. PMID 11698225 DOI: 10.1016/S1471-4906(01)02060-9 |
0.678 |
|
| 2001 |
Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, Caligiuri MA. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. European Journal of Immunology. 31: 3016-25. PMID 11592078 DOI: 10.1002/1521-4141(2001010)31:10<3016::Aid-Immu3016>3.0.Co;2-J |
0.493 |
|
| 2001 |
Baiocchi RA, Ward JS, Carrodeguas L, Eisenbeis CF, Peng R, Roychowdhury S, Vourganti S, Sekula T, O'Brien M, Moeschberger M, Caligiuri MA. GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder. The Journal of Clinical Investigation. 108: 887-94. PMID 11560958 DOI: 10.1172/Jci12932 |
0.719 |
|
| 2001 |
Alexander RL, Ramage J, Kucera GL, Caligiuri MA, Frankel AE. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein Leukemia Research. 25: 875-881. PMID 11532521 DOI: 10.1016/S0145-2126(01)00034-0 |
0.404 |
|
| 2001 |
Smiraglia DJ, Rush LJ, Frühwald MC, Dai Z, Held WA, Costello JF, Lang JC, Eng C, Li B, Wright FA, Caligiuri MA, Plass C. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies Human Molecular Genetics. 10: 1413-1419. PMID 11440994 DOI: 10.1093/Hmg/10.13.1413 |
0.685 |
|
| 2001 |
Fehniger TA, Suzuki K, VanDeusen JB, Cooper MA, Freud AG, Caligiuri MA. Fatal leukemia in interleukin-15 transgenic mice. Blood Cells, Molecules & Diseases. 27: 223-30. PMID 11358383 DOI: 10.1006/Bcmd.2001.0379 |
0.817 |
|
| 2001 |
Rush LJ, Dai Z, Smiraglia DJ, Gao X, Wright FA, Frühwald M, Costello JF, Held WA, Yu L, Krahe R, Kolitz JE, Bloomfield CD, Caligiuri MA, Plass C. Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci. Blood. 97: 3226-33. PMID 11342453 DOI: 10.1182/Blood.V97.10.3226 |
0.652 |
|
| 2001 |
Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 97: 3146-51. PMID 11342442 DOI: 10.1182/Blood.V97.10.3146 |
0.689 |
|
| 2001 |
Cooper MA, Fehniger TA, Ponnappan A, Mehta V, Wewers MD, Caligiuri MA. Interleukin-1beta costimulates interferon-gamma production by human natural killer cells. European Journal of Immunology. 31: 792-801. PMID 11241284 DOI: 10.1002/1521-4141(200103)31:3<792::Aid-Immu792>3.0.Co;2-U |
0.688 |
|
| 2001 |
Fehniger TA, Suzuki K, Ponnappan A, VanDeusen JB, Cooper MA, Florea SM, Freud AG, Robinson ML, Durbin J, Caligiuri MA. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. The Journal of Experimental Medicine. 193: 219-31. PMID 11208862 DOI: 10.1084/Jem.193.2.219 |
0.829 |
|
| 2001 |
Whitman SP, Strout MP, Marcucci G, Freud AG, Culley LL, Zeleznik-Le NJ, Mrózek K, Theil KS, Kees UR, Bloomfield CD, Caligiuri MA. The partial nontandem duplication of the MLL (ALL1) gene is a novel rearrangement that generates three distinct fusion transcripts in B-cell acute lymphoblastic leukemia. Cancer Research. 61: 59-63. PMID 11196198 |
0.607 |
|
| 2001 |
Virtaneva K, Wright FA, Tanner SM, Yuan B, Lemon WJ, Caligiuri MA, Bloomfield CD, de La Chapelle A, Krahe R. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proceedings of the National Academy of Sciences of the United States of America. 98: 1124-9. PMID 11158605 DOI: 10.1073/Pnas.98.3.1124 |
0.401 |
|
| 2001 |
Nuovo GJ, Morrison C, Porcu P, Caligiuri MA, Suster S. In situ determination of T-cell receptor beta expression patterns. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 49: 139-45. PMID 11156682 DOI: 10.1177/002215540104900201 |
0.355 |
|
| 2001 |
Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 97: 14-32. PMID 11133738 DOI: 10.1182/Blood.V97.1.14 |
0.362 |
|
| 2001 |
Caligiuri MA. IL-7: success without a formal education Blood. 97: 1523-1523. DOI: 10.1182/Blood.V97.6.1523 |
0.376 |
|
| 2000 |
Yang J, Tao Q, Flinn IW, Murray PG, Post LE, Ma H, Piantadosi S, Caligiuri MA, Ambinder RF. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: Disappearance after rituximab therapy does not predict clinical response Blood. 96: 4055-4063. PMID 11110673 DOI: 10.1182/Blood.V96.13.4055.H8004055_4055_4063 |
0.351 |
|
| 2000 |
Reuther GW, Lambert QT, Caligiuri MA, Der CJ. Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia. Molecular and Cellular Biology. 20: 8655-66. PMID 11073967 DOI: 10.1128/Mcb.20.23.8655-8666.2000 |
0.373 |
|
| 2000 |
Carson WE, Dierksheide JE, Jabbour S, Anghelina M, Bouchard P, Ku G, Yu H, Baumann H, Shah MH, Cooper MA, Durbin J, Caligiuri MA. Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction. Blood. 96: 1465-73. PMID 10942393 DOI: 10.1182/Blood.V96.4.1465.H8001465_1465_1473 |
0.667 |
|
| 2000 |
Fehniger TA, Bluman EM, Porter MM, Mrózek E, Cooper MA, VanDeusen JB, Frankel SR, Stock W, Caligiuri MA. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. The Journal of Clinical Investigation. 106: 117-24. PMID 10880055 DOI: 10.1172/Jci6218 |
0.815 |
|
| 2000 |
Ying AK, Hassanain HH, Roos CM, Smiraglia DJ, Issa JPJ, Michler RE, Caligiuri M, Plass C, Goldschmidt-Clermont PJ. Methylation of the estrogen receptor-α gene promoter is selectively increased in proliferating human aortic smooth muscle cells Cardiovascular Research. 46: 172-179. PMID 10727665 DOI: 10.1016/S0008-6363(00)00004-3 |
0.342 |
|
| 2000 |
Kourlas PJ, Strout MP, Becknell B, Veronese ML, Croce CM, Theil KS, Krahe R, Ruutu T, Knuutila S, Bloomfield CD, Caligiuri MA. Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 97: 2145-50. PMID 10681437 DOI: 10.1073/Pnas.040569197 |
0.301 |
|
| 2000 |
Fehniger TA, Yu H, Cooper MA, Suzuki K, Shah MH, Caligiuri MA. Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo. Journal of Immunology (Baltimore, Md. : 1950). 164: 1643-7. PMID 10657604 DOI: 10.4049/Jimmunol.164.4.1643 |
0.635 |
|
| 2000 |
Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomäki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nature Genetics. 24: 132-8. PMID 10655057 DOI: 10.1038/72785 |
0.663 |
|
| 1999 |
Baiocchi RA, Caligiuri MA. Cytokines in the evolution and treatment of AIDS-lymphoma. Current Opinion in Oncology. 11: 516-21. PMID 10550017 DOI: 10.1097/00001622-199911000-00014 |
0.326 |
|
| 1999 |
Fehniger TA, Carson WE, Caligiuri MA. Costimulation of human natural killer cells is required for interferon gamma production. Transplantation Proceedings. 31: 1476-8. PMID 10330974 DOI: 10.1016/S0041-1345(99)00011-1 |
0.447 |
|
| 1999 |
Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, Suzuki K, Wechser M, Goodsaid F, Caligiuri MA. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. Journal of Immunology (Baltimore, Md. : 1950). 162: 4511-20. PMID 10201989 |
0.781 |
|
| 1998 |
Khatri VP, Caligiuri MA. A review of the association between interleukin-10 and human B-cell malignancies. Cancer Immunology, Immunotherapy : Cii. 46: 239-44. PMID 9690451 DOI: 10.1007/S002620050483 |
0.357 |
|
| 1998 |
Shah MH, Hackshaw KV, Caligiuri MA, McInnes LB, Leung BP, Feng G.- J, Sturrock RD, Field M, Liew FY. A role for IL-15 in rheumatoid arthritis? [1] (multiple letters) Nature Medicine. 4: 643. PMID 9623950 DOI: 10.1038/Nm0698-643A |
0.317 |
|
| 1998 |
Khatri VP, Fehniger TA, Baiocchi RA, Yu F, Shah MH, Schiller DS, Gould M, Gazzinelli RT, Bernstein ZP, Caligiuri MA. Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. The Journal of Clinical Investigation. 101: 1373-8. PMID 9502779 DOI: 10.1172/Jci2038 |
0.419 |
|
| 1998 |
Yu H, Fehniger TA, Fuchshuber P, Thiel KS, Vivier E, Carson WE, Caligiuri MA. Flt3 Ligand Promotes the Generation of a Distinct CD34+Human Natural Killer Cell Progenitor That Responds to Interleukin-15 Blood. 92: 3647-3657. DOI: 10.1182/Blood.V92.10.3647.422K43_3647_3657 |
0.507 |
|
| 1998 |
Yu H, Fehniger TA, Fuchshuber P, Thiel KS, Vivier E, Carson WE, Caligiuri MA. Flt3 Ligand Promotes the Generation of a Distinct CD34+Human Natural Killer Cell Progenitor That Responds to Interleukin-15 Blood. 92: 3647-3657. DOI: 10.1182/blood.v92.10.3647 |
0.409 |
|
| 1997 |
Strout MP, Caligiuri MA. Developments in cytogenetics and oncogenes in acute leukemia. Current Opinion in Oncology. 9: 8-17. PMID 9090489 DOI: 10.1097/00001622-199701000-00003 |
0.308 |
|
| 1997 |
Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, Croce CM, Baumann H, Caligiuri MA. A potential role for interleukin-15 in the regulation of human natural killer cell survival. The Journal of Clinical Investigation. 99: 937-43. PMID 9062351 DOI: 10.1172/Jci119258 |
0.336 |
|
| 1997 |
Carson WE, Fehniger TA, Caligiuri MA. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. European Journal of Immunology. 27: 354-60. PMID 9045904 DOI: 10.1002/Eji.1830270203 |
0.399 |
|
| 1997 |
Fehniger TA, Carson WE, Mrózek E, Caligiuri MA. Stem Cell Factor Enhances Interleukin-2–Mediated Expansion of Murine Natural Killer Cells In Vivo Blood. 90: 3647-3653. DOI: 10.1182/Blood.V90.9.3647 |
0.389 |
|
| 1997 |
Baiocchi RA, Khatri VP, Lindemann MJ, Ross ME, Papoff G, Caprio AJ, Caprio TV, Fenstermaker R, Ruberti G, Bernstein ZP, Caligiuri MA. Phenotypic and Functional Analysis of Fas (CD95) Expression in Primary Central Nervous System Lymphoma of Patients With Acquired Immunodeficiency Syndrome Blood. 90: 1737-1746. DOI: 10.1182/Blood.V90.5.1737 |
0.388 |
|
| 1997 |
Ross ME, Caligiuri MA. Cytokine-Induced Apoptosis of Human Natural Killer Cells Identifies a Novel Mechanism to Regulate the Innate Immune Response Blood. 89: 910-918. DOI: 10.1182/BLOOD.V89.3.910 |
0.366 |
|
| 1997 |
Jurlander J, Lai C, Tan J, Chou C, Geisler CH, Schriber J, Blumenson LE, Narula SK, Baumann H, Caligiuri MA. Characterization of Interleukin-10 Receptor Expression on B-Cell Chronic Lymphocytic Leukemia Cells Blood. 89: 4146-4152. DOI: 10.1182/Blood.V89.11.4146 |
0.461 |
|
| 1997 |
Khatri VP, Yu F, baiocchi RA, Shah MH, Zwerling BH, Gould M, Bernstein ZP, Caligiuri MA. ANALYSIS OF TH1/TH2 CYTOKINE GENE PROFILE DURING LOW DOSE IL-2 THERAPY IN PATIENTS WITH AIDS OR AIDS LYMPHOMA Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 14: A41. DOI: 10.1097/00042560-199704010-00140 |
0.341 |
|
| 1996 |
Bluman EM, Bartynski KJ, Avalos BR, Caligiuri MA. Human natural killer cells produce abundant macrophage inflammatory protein-1 alpha in response to monocyte-derived cytokines. The Journal of Clinical Investigation. 97: 2722-7. PMID 8675682 DOI: 10.1172/JCI118726 |
0.301 |
|
| 1996 |
Bluman E, Schnier G, Avalos B, Strout M, Sultan H, Jacobson F, Williams D, Carson W, Caligiuri M. The c-kit ligand potentiates the allogeneic mixed lymphocyte reaction Blood. 88: 3887-3893. DOI: 10.1182/BLOOD.V88.10.3887.BLOODJOURNAL88103887 |
0.363 |
|
| 1996 |
Mrozek E, Anderson P, Caligiuri M. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells Blood. 87: 2632-2640. DOI: 10.1182/Blood.V87.7.2632.Bloodjournal8772632 |
0.372 |
|
| 1995 |
Carson WE, Ross ME, Baiocchi RA, Marien MJ, Boiani N, Grabstein K, Caligiuri MA. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-γ by natural killer cells in vitro Journal of Clinical Investigation. 96: 2578-2582. PMID 8675621 DOI: 10.1172/Jci118321 |
0.466 |
|
| 1995 |
Carson W, Lindemann M, Baiocchi R, Linett M, Tan J, Chou C, Narula S, Caligiuri M. The functional characterization of interleukin-10 receptor expression on human natural killer cells Blood. 85: 3577-3585. DOI: 10.1182/Blood.V85.12.3577.Bloodjournal85123577 |
0.379 |
|
| 1994 |
Baiocchi RA, Caligiuri MA. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 91: 5577-81. PMID 7911241 DOI: 10.1073/Pnas.91.12.5577 |
0.468 |
|
| 1994 |
Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K, Caligiuri MA. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. The Journal of Experimental Medicine. 180: 1395-403. PMID 7523571 DOI: 10.1084/Jem.180.4.1395 |
0.305 |
|
| 1994 |
Carson WE, Haldar S, Baiocchi RA, Croce CM, Caligiuri MA. The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2. Proceedings of the National Academy of Sciences of the United States of America. 91: 7553-7. PMID 7519782 DOI: 10.1073/Pnas.91.16.7553 |
0.457 |
|
| 1994 |
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice Nature. 367: 645-648. PMID 7509044 DOI: 10.1038/367645A0 |
0.367 |
|
| 1994 |
Gruss H, Hirschstein D, Wright B, Ulrich D, Caligiuri M, Barcos M, Strockbine L, Armitage R, Dower S. Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease Blood. 84: 2305-2314. DOI: 10.1182/blood.v84.7.2305.bloodjournal8472305 |
0.335 |
|
| 1993 |
Matos ME, Schnier GS, Beecher MS, Ashman LK, William DE, Caligiuri MA. Expression of a functional c-kit receptor on a subset of natural killer cells. The Journal of Experimental Medicine. 178: 1079-84. PMID 7688785 DOI: 10.1084/JEM.178.3.1079 |
0.374 |
|
| 1993 |
Caligiuri MA, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C, Schow P, Ross ME, Klumpp TR, Soiffer RJ, Smith KA, Ritz J. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2 Journal of Clinical Investigation. 91: 123-132. PMID 7678599 DOI: 10.1172/JCI116161 |
0.38 |
|
| 1990 |
Anderson P, Caligiuri M, O'Brien C, Manley T, Ritz J, Schlossman SF. Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells. Proceedings of the National Academy of Sciences of the United States of America. 87: 2274-8. PMID 2138330 DOI: 10.1073/Pnas.87.6.2274 |
0.42 |
|
| 1990 |
Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. The Journal of Experimental Medicine. 171: 1509-26. PMID 1692080 DOI: 10.1084/jem.171.5.1509 |
0.37 |
|
| 1989 |
Anderson P, Caligiuri M, Ritz J, Schlossman SF. CD3-negative natural killer cells express zeta TCR as part of a novel molecular complex. Nature. 341: 159-62. PMID 2528695 DOI: 10.1038/341159A0 |
0.347 |
|
| 1989 |
Caligiuri MA, Murray C, Levine H, Longtine JA, Ritz J. Clonal evidence for the induction of NKH1 on activated human thymocytes. Functional changes associated with antigen expression. European Journal of Immunology. 19: 1735-9. PMID 2477257 DOI: 10.1002/EJI.1830190931 |
0.369 |
|
| Show low-probability matches. |